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ABSTRACT
Colorectal cancer (CRC) is the third most frequent cancer and the second leading 
cause of cancer related deaths. While CRC is initiated by mutations in critical tumor 
suppressor genes, its development and progression to malignancy is aided by host derived 
cells that are recruited to the tumor microenvironment (TME) and by cancer-associated 
microbiota that constitute the gut microbiome. Components of the gut microbiota have 
been shown to alter immune cell infiltration into tumors and influence response to 
therapy, disease stage, and patient survival.  In previous studies, we found that Apc
Min/+
 
mice, a model of early colon carcinogenesis, had reduced tumor burden when weaned to 
a folate free (FF) diet as compared to mice weaned to regular rodent chow (RC). When 
subjected to systemic therapy with 5-FU, tumor response in mice on the folate free diet 
was more cytotoxic as compared to mice on rodent chow, where tumor response was only 
cytostatic, with tumor burden rebounding to untreated levels upon removal of 5-FU. 
 The goal of this study was to identify alterations in the gut microbiome 
composition in Apc
Min/+
mice on the different diets, RC, FF, and FF+FA. The FF and 
FF+FA diets are both defined diets that contain the antibiotic succinyl sulfathiazole 
(SST), which prevents the production and absorption of folate. The distinguishing factor 
amongst these diets was that the FF diet contains no folic acid (FA) and the FF+FA diet 
contains 6 parts per million (ppm) FA. The FF+FA diet contains similar levels of FA that 
are present in the crude RC diet, which is a standard diet for mice.  
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The results showed significant changes in the gut microbiome composition 
between RC, FF, and FF+FA diets with additional changes upon treatment with 5-FU. 
The Bacteroidetes S24-7 population was nearly eliminated in mice fed the FF and FF+FA 
diets, while the Firmicutes Ruminococcus and Clostridiales populations expanded. In 
addition, the concentration and production of metabolites, specifically short chain fatty 
acids (SCFAs), were significantly reduced when mice were fed the FF and FF+FA diets, 
and these levels remained at low levels during treatment with 5-FU. This correlated with 
reduced infiltration of immune cells into the TME. Mast cells, macrophages, myeloid 
derived suppressor cells (MDSCs), T-regulatory cells, and CD8 cytotoxic T cells were 
significantly reduced in the TME when mice were fed the FF and FF+FA diets, and these 
levels remained low during treatment with 5-FU. Although similar results were observed 
in mice fed the FF and FF+FA diets, tumor burden was reduced by 70% when mice fed 
the FF diet were treated with 5-FU as compared to untreated controls. Mice fed the 
FF+FA diet that were treated with 5-FU only had a mild 30% reduction in tumor burden 
as compared to untreated controls. These data suggest that elimination of folate from 
dietary intake and the gut microbiota was essential to enhance the cytotoxicity of 5-FU. 
However, because the FF and FF+FA diets are both defined diets and contain the 
antibiotic, SST, it was important to distinguish the effects of the removing dietary folate 
versus inhibiting gut microbe folate production. Mice were fed a basal and FF diet that 
were defined diets lacking SST, designated as basal and FF* diets, respectively, and then 
subjected to 5-FU therapy. The basal diet contained 6 ppm FA whereas the FF* diet 
contained no FA and no SST.   The results showed that removal of SST reversed the 
previous effects on the gut microbiota, ie, the Bacteroidetes S24-7 population was 
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restored and the Firmicutes Ruminococcus and Clostridiales populations returned to 
lower levels in mice fed the basal and FF* diets that was similar in abundance to that in 
mice fed the RC diet. However, the composition of SCFAs remained significantly lower 
in mice fed the basal and FF* diets, and remained low during treatment with 5-FU. The 
infiltration of mast cells, macrophages, MDSCs, and T-regulatory cells were significantly 
lower in the TME as compared to mice fed the FF and FF+FA diets containing SST. 
While tumor burden was 15% lower in mice fed the basal and FF* diets, treatment with 
5-FU caused a modest 30% reduction in tumor burden as as compared to untreated 
controls and similar to that observed in mice fed RC diet. These results highlight the 
importance of inhibiting folate production by the gut microbiota in influencing the 
activation and infiltration of immune cells into the TME, and enhancing the cytotoxic 
effects of 5-FU.  
These studies show that understanding the role of the gut microbiome in response 
to 5-FU could lead to the development therapeutic strategies targeting the gut 
microbiome to alter its metabolites in order to enhance the antitumor efficacy of 5-FU 
while minimizing its cytotoxic effects to the patient.
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1.1 COLORECTAL CANCER 
Colorectal cancer (CRC) is the third most frequent cancer and the third leading cause 
of cancer related deaths in the United States ("Cancer Facts and Figures"; Jin et al.). In 
2018, the American Cancer Society estimated that 140,250 new cases of CRC will be 
diagnosed and 50,630 deaths would occur ("American Cancer Society"; Jin et al.). 
Globally, the estimated incidence of CRC in 2012 was 1,360,000, and the estimated 
mortality was 694,000. Increased awareness and screening has reduced the mortality 
from the disease as CRC is being detected and treated at earlier stages (Pompei et al.;  
"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 
2012") when the survival rate is high. Early screening for CRC has proven to be highly 
effective as the incidence of CRC deaths has decreased by half since 1975 ("Cancer Facts 
and Figures"). Although polyps are starting to be detected and treated before they become 
malignant and invasive, the incidence of CRC has remained high and continues to 
increase, particularly in individuals under 50 years of age.  
Unfortunately, most of the steps leading to CRC progression are asymptomatic 
making its detection at an early stage, when intervention may prevent its progression, 
very difficult and problematic ("Cancer Facts and Figures"). By the time that CRC is 
diagnosed, only 40% of patients present with tumors at the early primary stages 
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suggesting that the majority of CRC is detected when the cancer has already metastasized 
("Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 
2012"; "Survival Rates for Colorectal Cancer, by Stage"). When CRC is detected at early 
stages, the five-year survival rate is greater than 90% ("Globocan 2012: Estimated Cancer 
Incidence, Mortality and Prevalence Worldwide in 2012"; "Survival Rates for Colorectal 
Cancer, by Stage"). However, when CRC has spread to lymph nodes and distant organs, 
the five-year survival rate drops dramatically to less than 12% (Figure 1.1) ("Cancer 
Facts and Figures"; "Survival Rates for Colorectal Cancer, by Stage"). Therefore, 
understanding the biological processes that drive tumor development and progression are 
crucial for the development of novel strategies for early detection and therapies to 
improve disease control and patient outcome.  
CRC is most frequently the result of sporadic, non-inheritable mutations in the 
adenomatous polyposis coli (APC) gene, and less than 5% of patients diagnosed with 
CRC will inherit a mutation in the APC gene in germ cells (A R Moser et al.; A. R. 
Moser et al.; Daniel et al.). Sporadic cancers begin with a mutation in the APC gene 
resulting in the formation of polyps and genomic instability (Daniel et al.; Fearon and 
Vogelstein). Subsequent mutations occur that turn off tumor-suppressor genes and turn 
on proto-oncogenes transforming the polyp into a malignant tumor (Daniel et al.; Fearon 
and Vogelstein). Additional mutations further modulate the tumor and its 
microenvironment enabling the its invasion through the basement membrane and 
metastasis to distant organs, most frequently, the liver and the lungs (Daniel et al.; Fearon 
and Vogelstein).   
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1.2 INHIBITORS OF THYMIDYLATE SYNTHASE: 5-FLUOROURACIL 
Thymidylate Synthase (TYMS) is an S-phase enzyme that catalyzes the reductive 
methylation of deoxyuridine monophosphate (dUMP) by methylene tetrahydrofolate 
(CH2H4PteGlu) to form deoxythymidine monophosphate (dTMP) (Figure 1.2B) 
(Longley, Harkin and Johnston; Information "2-Fluoropyrimidine"; Information 
"Fluorouracil"; Valeriote and Santelli) Uracil is one of the four nucleotides that are 
incorporated into RNA. Methylation of uracil at the C-5 position produces thymine which 
is one of the four nucleotides that become incorporated into DNA during synthesis. 
TYMS is the enzyme that catalyzes this conversion and this enzymatic reaction is the sole 
source of dTMP for DNA synthesis in rapidly proliferating cells thus, TYMS is a critical 
target for anti-cancer agents (Information "Fluorouracil"; Information "2-
Fluoropyrimidine"; Longley, Harkin and Johnston).  
5-Fluorouracil (5-FU) is an analogue of uracil that contains a fluorine atom at the C-5 
position instead of a hydrogen atom (Figure 1.2A) (Information "2-Fluoropyrimidine"). 
5-FU is an antimetabolite that functions dually by (1) inhibiting the S-phase enzyme 
TYMS and (2) misincorporating fluoropyrimidines into DNA and RNA (Jin et al.; 
Longley, Harkin and Johnston; Information "Fluorouracil").   
Mechanistically, the substrate fluoro-deoxyuridine monophosphate (FdUMP) binds to 
the nucleotide binding site of TYMS and forms a stable ternary complex with the enzyme 
and the cofactor methylene tetrahydrofolate (CH2H4PteGlu), and thereby blocking the 
binding of the normal substrate, dUMP (Longley, Harkin and Johnston) and resulting in a 
dead enzyme. 5-FU can also be mis-incorporated into DNA and RNA which results in 
DNA or RNA fragmentation. TYMS inhibition results in depletion of dTMP leading to 
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an imbalance of the deoxynucleotide pool. A disruption specifically in the ratio of 
deoxyadenosine triphosphate (dATP) and deoxythymidine triphosphate (dTTP) is thought 
to interfere with DNA synthesis and repair and therefore causes severe DNA damage 
(Longley, Harkin and Johnston). Studies have shown that 5-FU also disrupts the 
processing of pre-rRNA into mature rRNA, post-transcriptional modifications of tRNA, 
the assembly and activity of snRNA, and splicing of pre-mRNA (Longley, Harkin and 
Johnston; Information "Fluorouracil"). All of these result in apoptosis and cell death. 
Despite the importance of this pathway for cell growth, 5-FU is only mildly effective 
with only 10% of patients exhibiting a positive response (Longley, Harkin and Johnston; 
Johnston and Kaye). However, when 5-FU is combined with other therapies, the efficacy 
is enhanced in up to 40% of patients (Longley, Harkin and Johnston; Giacchetti et al.). 
For example, Leucovorin (LV), or folinic acid, expands the concentrations of CH2THF, 
which stabilizes the binding of TS and FdUMP (Wright et al.; Yasuhiko et al.). Wright et 
al. showed that treatment of Balb/c mice that had a subcutaneous injection of the murine 
mammary carcinoma cell line, EMT6, with a combination therapy of 5-FU + LV showed 
a significant delay in tumor growth as compared to mice treated with 5-FU alone (Wright 
et al.). Mice administered with 5-FU had larger tumors as compared to mice treated with 
5-FU + LV (Wright et al.), while treatment with LV alone had no significant impact on 
tumor growth (Wright et al.). In support of this findings, Nadal et al. used murine colon 
cancer cells lines, CT26 (Balb/c) and MC38 (C57Bl/6), to show that pretreatment with 
LV before and during treatment with 5-FU significantly delayed the growth and 
development of subcutaneous tumors (Nadal). In balb/c mice implanted with CT26 cells, 
treatment with 5-FU + LV significantly delayed tumor growth by approximately three-
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fold as compared to treatment with 5-FU alone (Nadal). In C57Bl/6 mice implanted with 
MC38 cells, treatment with 5-FU + LV also significantly delayed tumor growth as 
compared to treatment with 5-FU alone (Nadal). Similar results were also observed in 
vitro when LV was combined with 5-FU treatment (Nadal). Consistent with these results, 
Park et al. showed that treatment with 5-FU + LV resulted in 50% growth inhibition in 
four human colorectal cancer cell lines, while treatment with 5-FU alone resulted in a 
50% growth inhibition in three cell lines (Park et al.). Irinotecan is another anti-cancer 
compound that when activated by hydrolysis to SN-38, inhibits the function of 
topoisomerase I, which plays a variety of roles during DNA replication and cell division 
(Douillard et al.).  Douillard et al. showed that the response rate increased by 18% in 
patients receiving irinotecan combined with 5-FU as compared patients not receiving 
irinotecan alone (Douillard et al.). The time to recurrence, duration of response, and 
survival were prolonged in patients receiving irinotecan recipient as compared to those 
who did not receive the drug (Douillard et al.). Another common treatment, methotrexate 
(MTX), is an antimetabolite drug. MTX is an antifolate that inhibits dihydrofolate 
reductase, an enzyme that participates in tetrahydrofolate synthesis by regenerating 
methylene tetrahydrofolate, the co-factor (Cronstein). Because tetrahydrofolate is 
required for thymine biosynthesis, methotrexate interferes with DNA replication and the 
cell cycle (Cronstein). In patients with advanced colorectal cancer, tumor response is 
nearly doubled when 5-FU was supplemented with MTX ("Meta-Analysis of 
Randomized Trials Testing the Biochemical Modulation of Fluorouracil by Methotrexate 
in Metastatic Colorectal Cancer. Advanced Colorectal Cancer Meta-Analysis Project"). 
This data positively correlated with an increase in overall survival ("Meta-Analysis of 
6 
Randomized Trials Testing the Biochemical Modulation of Fluorouracil by Methotrexate 
in Metastatic Colorectal Cancer. Advanced Colorectal Cancer Meta-Analysis Project"). 
Lastly, interferons (IFNs) are considered potent inhibitors of tumor cell growth. IFN-α 
activates natural killer (NK) cells and macrophages that target and destroy tumor cells. 
IFN-α is also thought to work with 5-FU to prevent tumor growth (Villar-Grimalt et al.). 
Villar-Grimalt et al. showed that patients treated with IFN-β, an IFN with greater anti-
proliferative activity, and 5-FU showed a 28.8% increase in tumor response (Villar-
Grimalt et al.). The improved response positively correlated with slower tumor 
progression, increased survival, and no significant impact on toxicity (Villar-Grimalt et 
al.).  
The use of 5-FU in the clinic has been severely limited by toxicity to rapidly dividing 
normal cells and acquired resistance (Malet-Martino and Martino). Resistance to 5-FU 
has been shown to occur through various mechanisms such as increased TYMS protein 
levels, TYMS gene amplification, and/or decreased inhibition of TYMS activity (Jin et 
al.). An increase in TYMS activity undermines the activity of 5-FU, which functions to 
block this enzymatic pathway. When a tumor acquires mechanisms to overcome the 
inhibition by 5-FU, the drug loses its efficacy and the tumor begins to rapidly grow and 
divide. This ultimately leads to metastasis and poor patient prognosis. Therefore, it is 
essential to discover novel therapeutic strategies to increase the efficacy of 5-FU while 
avoiding toxicity and acquired resistance. Targeting other molecules in this pathway may 
promote tumor rejection and prevent chemo-resistance. For example, targeting the gut 
microbiota during 5-FU treatment may further influence the activity of TYMS and serve 
as a powerful tool to suppress its enzymatic activity.      
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1.3 FOLATE 
Folate is a water soluble vitamin frequently referred to as vitamin B9 (Clinic). A 
synthetic version of folate, folic acid (FA) is a very stable compound that is quickly 
absorbed by the body; however FA is not well utilized by the body. Folate is a necessary 
cofactor in many biological processes including the biosynthesis of amino acids and 
nucleotides such as histidine, serine, glycine, methionine, thymidylate, and purine. In 
addition, folate is essential in red blood cell formation (Mahmood). A deficiency in folate 
can therefore lead to anemia (Bailey and Gregory; Mahmood; Clinic). Folate is most 
commonly known for its importance during pregnancy to prevent neural tube defects, or 
brain and spine birth defects (Bailey and Gregory; Mahmood; Clinic). Relevant to this 
study, during the synthesis of thymidine, FA is converted to methylene tetrahydrofolate 
(CH2H4PteGlu) where it functions as a co-factor of TYMS (Longley, Harkin and 
Johnston). Therefore, FA metabolism plays a crucial role in TYMS function and DNA 
synthesis.  
Folate is a vitamin that is not produced by the body, but is obtained through dietary 
intake of folate rich foods or vitamin supplements. Folate is rich in dark leafy green 
vegetables, beans, nuts, and fruits such as oranges, bananas, and strawberries (Mahmood; 
Clinic). In addition, folate is produced by microbes in the gut. Bacteroidetes, 
Fusobacteria, and Proteobacteria are considered as the common producers of folate 
whereas Actinobacteria and Firmicutes are considered the rare folate producers 
(Magnúsdóttir et al.; Rossi, Amaretti and Raimondi). Strains of Bifidobacterium, a 
probiotic genera, are also capable of producing folate (Rossi, Amaretti and Raimondi). 
Rats fed a probiotic formula containing folate producing bacteria have increased levels of 
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plasma folate. In addition, humans fed the same probiotic formula showed increased 
levels of folate in their feces suggesting that the gut microbiota may play a critical role in 
folate synthesis and circulating levels (Pompei et al.).  
1.4 GUT MICROBIOTA 
The gut microbiota is comprised of trillions of microorganisms inhabiting the small 
intestine, colon, and rectum. The human gut contains approximately 1000 known 
bacterial species with more than 3 million genes (Guinane and Cotter). Further increasing 
its complexity, each individual’s gut microbiota is unique with only approximately 30% 
similarity amongst other individuals. The gut microbiota is like a fingerprint, where no 
two individuals have exactly the same composition (Gilbert). It is very unique and 
dynamic across individuals which makes learning and understanding its function very 
complicated. The gut microbiota varies across individuals within a population due to a 
variety of factors. Each individual’s microbiota coevolves with the individual as a result 
of age, diet, exercise, geographic location, and exposure to various factors such as 
antibiotics, drugs, among others (Brennan and Garrett; Lagier et al.; Levy et al.; Moya 
and Ferrer; Schubert, Sinani and D Schloss).  
In recent years, the gut microbiome has become an important focus of research. Many 
studies over the last decade have shown that the gut microbiome plays an important role 
in the healthy development of an individual as well as in the development and 
progression of many diseases including but not limited to obesity, diabetes, arthritis, 
colitis, and cancer (Brennan and Garrett; Iida et al.; Levy et al.; Malinen et al.; Moya and 
Ferrer). Imbalances in the gut microbiota, or dysbiosis, can be detrimental to human 
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health. Dysbiosis has been shown to be harmful to the host’s metabolism, physiology, 
nutrition, and immune function (Iida et al.; Moya and Ferrer).  
Relevant to this study is the fact that genetic mutations modify the gut microbiome 
and modulate the development of diseases like colorectal cancer or colitis (Brennan and 
Garrett; Couturier-Maillard et al.; Garrett et al.; Levy et al.). For example, Couturier-
Maillard et al. showed that Nucleotide-binding Oligomerization Domain-containing 
protein 2 (NOD2) deficient mice increased the risk of colitis to cohoused wild type (WT) 
mice (Couturier-Maillard et al.). NOD2 is a protein that is expressed by numerous cell 
populations within the colonic mucosa and maintains microbial tolerance at the intestinal 
barrier (Couturier-Maillard et al.). NOD2 deficient mice characteristically have an 
expansion of fecal and ileal-associated Bacteroidaceae, which closely mimics the 
expansion of Bacteroidaceae observed in humans carrying the NOD2 variant 
L1007fsinsC (Couturier-Maillard et al.). In this study, treatment with broad-spectrum 
antibiotics reduced the severity of colitis-driven tumorigenesis, as indicated by a 
reduction in body weight loss, and decreased the time to progression in both NOD2 
deficient and WT mice (Couturier-Maillard et al.). This study suggested that genetic 
mutations in critical intestinal barrier and immune regulator genes modified the gut 
microbiota which then enhanced inflammation driven diseases like colitis (Couturier-
Maillard et al.). In support of this notion, Garrett et al. showed that T-bet deficient mice 
are more susceptible to colitis when administered dextran sodium sulfate (DSS) (Garrett 
et al.). T-bet is a transcription factor that influences the innate and adaptive pro-
inflammatory immune responses (Garrett et al.). T-bet deficient mice displayed a more 
severe immune response as indicated by an increase in neutrophils, mononuclear cells, 
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and lymphoid aggregates (Garrett et al.). T-bet deficient mice also suffered from 
enhanced edema, ulceration, and intestinal crypt loss (Garrett et al.). In addition, cross 
fostering recombination activating gene 2 (Rag2) deficient mice, that lack the ability to 
generate mature B and T lymphocytes, and WT mice to mothers that were T-bet and 
Rag2 double deficient that have severe ulcerative colitis, significantly increased the 
colitis histology score of both Rag2-deficient and WT mice as compared to mice that 
were nursed by their own mothers (Garrett et al.). This study highlights the capability of 
the gut microbiota to initiate colitis by acquiring pathogenic gut microbiota from the 
cross fostered mother, despite the genetic resistance to colitis in the WT mice (Garrett et 
al.). Finally, Levy et al. used the nucleotide-binding domain, leucine-rich repeat-
containing Protein 6, apoptosis-associated speck-like protein (Nlrp6-Asc) containing a C-
terminal caspase recruitment domain (CARD) inflammasome deficiency model to show 
that fecal transfer from Nlrp6 deficient mice into WT mice through cohousing promoted 
dysbiosis despite the genetic resistance to gut dysbiosis (Levy et al.). Nlrp6 is present 
mainly in intestinal epithelial cells and is important for proliferation, mucus secretion, 
and mucosal self-renewal (Levy et al.). Mice deficient in Nlrp6 exhibit a distinct gut 
microbiota that pre-disposes them to inflammation-induced colorectal cancer among 
other intestinal complications (Levy et al.). In addition, Asc is a gene that is 
predominantly expressed in intestinal epithelial cells and mice deficient in Asc have gut 
dysbiosis that drives inflammation-induced colorectal cancer (Levy et al.). Interestingly, 
when germ free (GF) WT mice were cohoused with WT or Asc deficient mice, the GF 
mice adopted the gut microbiota composition and diversity of the WT or Asc deficient 
mice that they were housed with (Levy et al.). As a result, previously GF WT mice 
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housed with Asc deficient mice showed a significant reduction in colonic Interleukin-18 
(IL-18) levels, a symptom associated with Asc deficient mice (Levy et al.).  
Numerous studies have established that the gut microbiota is distinct in patients with 
several different diseases from that of healthy individuals and that bacteria present in the 
gut can promote or inhibit disease progression (Baxter et al.; Levy et al.; Couturier-
Maillard et al.; Elinav et al.; Garrett et al.; Henao-Mejia et al.; Ivanov et al.). In studies 
using GF mice, Baxter et al. showed that transplantation of fecal material from three 
healthy individuals and three CRC patients revealed six unique microbial profiles (Baxter 
et al.). Using an inflammation model of colorectal carcinogenesis, azoxmethane-dextran 
sodium sulfate (AOM-DSS), mice received fecal transplant before AOM-DSS exposure 
(Baxter et al.). The tumor burden was significantly different among mice receiving 
different fecal material and was associated with the microbes present in the gut rather 
than the stage of cancer of the fecal donor patient (Baxter et al.). In particular, the 
Bacteroidetes B. uniformis, B. fragilis, B. ovatus, B. xylanisolvens, and B. 
thetaiotamicron, were the species that were heavily associated with higher tumor burden 
(Baxter et al.). On the other hand, the Clostridium group was associated with lower tumor 
burden (Baxter et al.). These microbial shifts in the gut were derived from donor mice 
after the fecal transplant and prior to receiving the AOM-DSS treatment (Baxter et al.). 
However, during treatment with AOM-DSS, the gut microbiome changed the most in the 
mice that had the lowest tumor burden, whereas mice with the highest tumor burden 
showed the least amount of change in the gut microbiome composition (Baxter et al.). 
Conclusions from this study indicated that the mice whose initial community was closer 
to the tumor-associated end point community presented with a higher tumor burden 
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(Baxter et al.). Consistent with these results, fecal transplantation from mice with 
diseases such as non-alcohol fatty liver disease, obesity, colitis, and CRC, into healthy 
wild type (WT) mice increased the susceptibility of developing these diseases in the 
recipient mice (Levy et al.; Couturier-Maillard et al.; Elinav et al.; Garrett et al.; Henao-
Mejia et al.; Ivanov et al.).  
It is hypothesized that changes in the gut microbiota can promote or enhance 
tumorigenesis (Rubinstein et al.; Kostic, Chun, et al.; Kostic, Gevers, et al.; Castellarin et 
al.; Zackular, Baxter, Iverson, et al.; Zackular, Baxter, Chen, et al.; Zackular, Rogers, et 
al.). For example, colonization of Apc
Min/+
 mice with Fusobacterium nucleatum (F. 
nucleatum) promoted tumor progression and created a pro-inflammatory tumor 
microenvironment through the enhanced recruitment of myeloid cells (Rubinstein et al.; 
Kostic, Chun, et al.). Specifically, Rubinstien et al. showed that treatment of a variety of 
CRC cell lines, HCT116, DLD1, SW480, and HT29, with F. nucleatum increased growth 
stimulation by approximately100% (Rubinstein et al.). The mechanism of action 
indicated that F. nucleatum contained a virulence factor, FadA, that binds to E-cadherin 
on CRC cells (Rubinstein et al.). The interaction between FadA and E-cadherin enhanced 
the adherence and invasive properties of F. nucleatum to promote E-cadherin-mediated 
colorectal tumor growth (Rubinstein et al.). Consistent with the cell culture model, CRC 
patients have been shown to have elevated levels of the FadA gene as compared to 
healthy individuals (Rubinstein et al.). In support of these findings, Kostic et al. showed 
that CRC patients had an abundance of Fusobacterium spp. in their stool samples at a 
level significantly higher than healthy individuals (Kostic, Chun, et al.). In addition, 
colonizing Apc
Min/+
mice with Fusobacterium spp. enhanced the growth and development 
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of intestinal tumors, by specifically activating and increasing the infiltration of myeloid 
cells (Kostic, Chun, et al.). In particular, myeloid-derived suppressor cells (MDSCs) are 
known to play a potent role in suppressing the immune response (Kostic, Chun, et al.). 
The results indicated a 3.7-fold increase in MDSCs when Apc
Min/+
 mice were fed 
Fusobacterium spp. as compared to the control group (Kostic, Chun, et al.). In support of 
this notion, Castellarin et al. used RNA-sequencing to show that nine out of eleven 
patients had at least a 2-fold increase in F. nucleatum in the tumor tissue as compared to 
the adjacent healthy tissue (Castellarin et al.).  
Aside from F. nucleatum, studies using the AOM-DSS model have shown that 
conventionalizing germ-free (GF) mice with the microbiota of tumor-bearing mice 
subjected to AOM-DSS increased tumor formation suggesting that negatively altering the 
gut microbiota through inflammation contributes to tumorigenesis (Zackular, Baxter, 
Iverson, et al.). Targeting the gut microbiota therefore may be a powerful strategy to 
prevent inflammation and tumor development. In support of this notion, Zackukar et al. 
showed that administering different antibiotic cocktails to specific-pathogen free (SPF) 
mice subjected to the AOM-DSS inflammation based model of CRC altered their 
susceptibility to tumor development (Zackular, Baxter, Chen, et al.). In this study, 
administration of eight different combinations of metronidazole, streptomycin, and 
vancomycin into mice resulted in unique gut microbial profiles and subsequently, distinct 
differences in tumor burden (Zackular, Baxter, Chen, et al.). These data suggest that 
susceptibility to tumorigenesis may be altered by manipulating the microbial community 
present in the gut. However, the time at which the gut microbiota is manipulated appears 
to be critical. 
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Although the gut microbiota plays an essential role in tumorigenesis and progression, 
there is also strong evidence suggesting that the gut microbiota can determine the 
efficacy and toxicity of chemotherapy (Iida et al.; Yu et al.; Scott et al.; Alexander et al.). 
Iida et al. demonstrated the significance of intact commensal microbes in promoting 
tumor development (Iida et al.). Using GF mice or conventional mice treated with 
antibiotics, they showed that a modulated gut microbiota altered the tumor 
microenvironment (TME), specifically the function of myeloid derived suppressor cells 
(MDSCs) (Iida et al.). When subjected to oxaliplatin chemotherapy, mice with an altered 
microbiota had decreased tumor regression and survival as a result of MDSCs in the 
TME suppressing cytokine production, necrosis, reactive oxygen species (ROS), and 
cytotoxicity (Iida et al.).  In addition, Yu et al. showed that CRC patients with recurrent 
tumors following the combined chemotherapy treatment of oxaliplatin and capecitabine 
have an abundance of F. nucleatum (Yu et al.). This bacterium was shown to activate 
cancer cell autophagy, a survival mechanism used by cancer cells during environmental 
stress. The autophagy pathway promoted chemo-resistance through the activation of the 
toll-like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MYD88) 
pathway (Yu et al.). TLR4 is a pathogen recognition receptor that interacts with the 
adaptor molecular MYD88, which facilitates the production of pro-inflammatory 
cytokines like IL-6 and Tumor Necrosis Factor- α (TNF-α) (Lei Zhou). This pathway is 
involved in tumor invasion and migration, and allows the tumor to avoid immune 
surveillance and apoptosis. In addition, the MYD88-TLR4 pathway is known to promote 
tumor development and chemo-resistance (X. Chen et al.). In CRC, TLR4 expression is 
oncogenic, and TLR4 and MYD88 are elevated in patients with aggressive metastatic 
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CRC (Wang et al.; White; Yu et al.).  Thus, the gut microbiota is complex and can impact 
tumor development, progression, and host survival. Determining the changes in the gut 
microbiota during CRC development and treatment is essential to developing therapies to 
improve patient prognosis.  
1.5 TUMOR IMMUNE MICROENVIRONMENT 
Historically it was thought that a tumor was comprised of a homogenous population 
of highly proliferative cancerous cells. Thus, therapies were developed to specifically 
target rapidly dividing tumor cells. However, patient relapse and tumor recurrence after 
therapeutic intervention was frequent (Young et al.). In the last two decades, it has now 
been e that tumors are complex tissues composed of a heterogeneous population of tumor 
cells that are highly infiltrated with an equally heterogeneous population of non-
neoplastic cells that together with the extracellular matrix, where the tumor is embedded, 
comprise the tumor microenvironment (TME).  The heterogeneous collection of tumor-
associated non-neoplastic cells play a critical role in the function and dynamics of the 
tumor growth and progression to malignancy (Figure 1.3) (DeClerck et al.; Balkwill, 
Capasso and Hagemann; Quail and Joyce).  
The cells in the TME include endothelial cells, fibroblasts, innate and adaptive 
immune cells that secrete a complex combination of cytokines, chemokines, and growth 
factors that have been shown to impact tumor initiation, progression, and response to 
therapy (Lagier et al.). In addition, host and tumor interactions have been shown to be 
critical for epithelial to mesenchymal transition, tumor invasion and progression to 
metastasis (Y. Zhang et al.; DeClerck et al.; Trédan et al.). There is evidence showing 
that the tumor cells closely interact with the host immune system during progression to 
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malignancy (Y. Zhang et al.). In addition, numerous studies on host-tumor interactions 
and signaling have shown that the TME plays a major role in the development and 
treatment of cancers (Quail and Joyce; Trédan et al.; Peddareddigari, Wang and DuBois; 
Miselis et al.; Lin, Nguyen, et al.; Zeisberger et al.; Lin, Li, et al.; Gounaris et al.; Maltby, 
Khazaie and McNagny; Yasuhiko et al.; Kitadai et al.; Crawford et al.; Francia, 
Emmenegger and Kerbel; Ryan et al.; O'Callaghan et al.; M.-L. Chen et al.).  
For example, Gounaris et al. showed that human CRC tumors and two tumor-bearing 
mouse models of CRC had an abundance of mast cells infiltrating the tumor stroma and 
submucosa (Gounaris et al.). The mouse models used in this study were the Apc
Min/+
 
mouse and the tamoxifen-inducible Cre recombinase model to produce a mouse strain 
that had a stable dominant-acting mutant β-catenin (Gounaris et al.). In addition, TNF-α 
was shown to play a potent role in stimulating mast cell colony formation. Treatment of 
Apc
Min/+
 mice with anti-TNF-α antibodies significantly reduced the number of polyps 
observed (Gounaris et al.). The polyps present in the mice treated with anti-TNF-α also 
had a unique morphology which correlated with a four-fold decrease in the blood vessel 
volume and approximately a four-to five-fold decrease in mast cell progenitors (Gounaris 
et al.). To confirm the necessity of mast cells for polyp formation, Gounaris et al. lethally 
irradiated Apc
Min/+
 mice and reconstituted their bone marrow (BM) with WT marrow as 





(Gounaris et al.). Cd34 and Cd43 genes do not impact mast 
cell formation; however they are essential for permitting mast cells to traffic into the 
peripheral tissues (Gounaris et al.). Apc
Min/+





had a significant mast cell depletion and a significant reduction in the number of polyps 
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compared to WT BM recipients (Gounaris et al.). These mice also exhibited decreased 
blood vessel densities, decreased mitotic activity, and increased apoptosis of atypical 
epithelial cells (Gounaris et al.). Collectively, these data suggest that polyp formation is 
highly dependent on mast cells that create a tumor promoting microenvironment. In 
support of this notion, Strouch et al. showed that patients with pancreatic cancer had a 
significant increase in mast cells infiltration of the tumor stroma compared to healthy 
adjacent tissues (Strouch et al.). In addition, elevated mast cell infiltration correlated with 
advanced tumor stage (Strouch et al.). Studies in cell culture showed that the primary 
pancreatic cancer cell line, PANC1-1, and the metastatic pancreatic cancer cell line, 
AsPC1, induced the migration of the mast cell line LAD-2 at higher rates as compared to 
a normal human epithelial cell line, HPDE (Strouch et al.). In addition, co-culturing the 
PANC-a and AsPC1 pancreatic cell lines with LAD-2 cells significantly increased their 
proliferation (Strouch et al.). Taken together, these studies highlighted the necessity of 
mast cells in tumor formation, development, and progression. Targeting harmful immune 
cells in the tumor stroma such as mast cells may be a valuable strategy to reduce tumor 
burden and improve prognosis. 
Further studies by Miselis et al. showed that C57Bl/6 mice receiving an 
intraperitoneal injection of asbestos-induced mesothelioma cells had an abundance of 
macrophages in tumor spheroids and solid tumors (Miselis et al.). Liposome-encapsulated 
clodronate (CLIP) is known to prolong the depletion of macrophages and tumor 
associated macrophages (Miselis et al.). In this study, Miselis et al. showed that IP 
injection of CLIP into tumor-bearing mice caused macrophages to undergo apoptosis 
(Miselis et al.). In addition, mice treated with CLIP exhibited smaller residual tumors 
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whereas mice treated with PBS had extensive tumor growth and invasion in the 
diaphragm (Miselis et al.). Treatment with CLIP resulted in a 17-fold reduction in tumor 
burden, thus highlighting the potent impact of peritoneal macrophages in promoting the 
growth and survival of mesothelioma cells (Miselis et al.). In support of this studies, 
Zeisberger et al. showed that CD1-nude mice receiving a subcutaneous injection of 
murine F9 teratocarcinoma or human A673 rhabdomyosarcoma cells and treated with 
CLIP had reduced infiltration of macrophages that resulted in slower tumor growth 
(Zeisberger et al.). In addition, their results indicated that neutralizing Vascular 
Endothelial Growth Factor (VEGF) and blocking angiogenesis with an anti-VEGF 
antibody, SZH9, further decreased tumor burden (Zeisberger et al.). In mice injected with 
the A673 cells, treatment with CLIP alone caused a 63% decrease in tumor volume while 
treatment with SZH9 alone resulted in a 59% decrease (Zeisberger et al.). However, the 
combined therapy resulted in a 74% reduction in tumor volume indicating that depleting 
macrophages and blocking VEGF-dependent angiogenesis mas more effective in 
inhibiting tumor development and progression (Zeisberger et al.).  Lin et al. further 
showed that mammary lesions in PyMT mice, a mouse model of breast cancer metastasis, 
showed dense clusters of macrophages in the tumor stroma that preceded angiogenesis 
(Lin, Li, et al.). Because the CSF-1R promoter is expressed in macrophages, CSF-a null 
mutant mice showed a decrease in malignancy that was driven by a delay in angiogenesis 
and a low density of macrophages (Lin, Li, et al.). In addition, the dense blood vessel 
network did not develop in CSF-null mice as compared to WT mice, that developed 
dense vessel networks in the mammary lesions as early as 8 weeks (Lin, Li, et al.).     
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Myeloid-derived suppressor cells are another harmful immune cell population in the 
tumor stroma that play a major role in tumor recurrence after treatment. Danilin et al. 
showed that nude mice injected with MDA-MB-231 breast cancer cells into the 
mammary fat pad had an abundance of MDSCs in the bone marrow (Danilin et al.). To 
further elucidate the role of MDSCs, MDA-MB-231 cells were co-injected with naive 
immature myeloid cells (iMCs) or tumor-induced MDSCs. Co-injection of MDA-MB-
231 cells and tumor-induced MDSCs increased the tumor volume by 2.7-fold and 
simultaneously decreased the bone volume by 30% (Danilin et al.). These results 
suggested that tumor-induced MDSCs created a microenvironment that favored growth of 
breast cancer and loss of bone density. In support of these observations, athymic nude 
mice that were co-injected with MDA-MB-231 cells in the left cardiac ventricle and 
tumor-induced MDSCs in the tibia developed significantly larger tumors in the bone and 
more osteolytic lesions compared to mice injected with iMCs, thus highlighting the 
ability of MDSCs to promote bone destruction (Danilin et al.). In cell culture studies, 
MDA-MB-231 cells co-cultured with tumor-induced MDSCs exhibited elevated 
expression of the osteolytic factors, GLI2 and PTHRP in a transforming growth factor-β 
(TGF-β) dependent manner (Danilin et al.). This study suggested that MDSCs utilize 
their immunosuppressive function to promote tumor growth and drive breast-cancer 
associated osteolysis. In addition, Nagaraj et al. used the synthetic triterpenoid, methyl 
ester of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic (CDDO-ME; bardoxolone 
methyl), a powerful activator of the transcription factor nuclear factor-erythroid 2-related 
factor 2 (NRF2), that is involved in the upregulation of numerous anti-oxidant genes, to 
target MDSCs in tumors (Nagaraj et al.). Because MDSCs promote tumor development 
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by producing ROS, MDSCs were isolated from EL-4 thymoma tumor-bearing C7Bl/6 
mice and treated with CDDO-Me (Nagaraj et al.). The viability of MDSCs was 
significant impacted by CDDO-ME, and the levels of ROS were significant reduced 
(Nagaraj et al.). In addition, MDSCs are known to inhibit antigen-specific CD8
+
 T cell 
activity (Nagaraj et al.). Co-culturing MDSCs derived from EL-4 tumor bearing mice 
with OT-1 T cells and CDDO-Me abrogated the suppressive activity of MDSCs on CD8
+
 
T cells (Nagaraj et al.). In vivo, Nagaraj et al. found that CDDO-Me was able to inhibit 
the suppressive activity of MDSCs on CD8
+
 T cells in mice implanted with EL-4, LLC 
lung carcinoma, and MC38 colon carcinoma (Nagaraj et al.). Together these studies 
established the impact of MDSCs in tumor development and progression. Targeting 
MDSCs and inhibiting their immunosuppressive function may be a potent strategy to 
promote CD8
+
 T cell-mediate cytotoxicity. 
Finally, the immune-tolerant immune cell population, t-regulatory (Treg) cells, are 
known to suppress pro-inflammatory responses and control the function and activity of 
cytotoxic CD8
+
 T cells, an immune cell population that are potent tumor cell killers 
(Antony et al.). Shifting the balance of these two adaptive immune cell populations can 
facilitate a pro-inflammatory or anti-inflammatory immune responses (Antony et al.). An 
abundance of Treg cells for example promotes an anti-inflammatory response whereas an 
abundance of CD8
+
 T cells enhances a pro-inflammatory response (Antony et al.). In 
addition, evidence showed that CD8
+
 T cell immunity is mediated by CD4
+
 T-helper (Th) 
cells (Antony et al.).Under malignant conditions, an abundance of Treg cells correlated 
with poor survival in hepatocellular carcinoma (HCC) patients (Fu et al.). In this study, 
Fu et al. showed that circulating levels of Treg cells were significantly increased in HCC 
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patients as compared to healthy individuals (Fu et al.).  In addition, Treg cells 
accumulated more in the tumor region as compared to adjacent healthy tissue and 
increased in numbers with advancing cancer stage (Fu et al.). Further studies also showed 
that Treg cells blocked the production of CD8
+
 T cells in HCC patients (Fu et al.). 
Furthermore, Chen et al. generated a murine colon cancer cell line CT44, by stably 
transfecting CT26 cells with EGFP protein fused to Hemophilius influenzae HA epitope.  
Balb/c mice were subcutaneously injected with HA
+
 CT44 or HA
-
 CT26 cells to study the 
interaction between Treg cells and CD8
+
 T cells (M.-L. Chen et al.). Adoptive transfer of 
naive CD8
+
 T cells with a transgenic TCR specific for Kd-restricted HA512-520 peptide 
(HA specific CD8 cells) prior to tumor challenge of HA
+
 CT44 cells resulted in tumor 
rejection, while HA
-
 CT26 cells were not rejected (M.-L. Chen et al.). However, adoptive 
transfer of HA specific CD8
+
 T cells and HA specific CD4
+
 Treg cells prior to CD44 
tumor challenge showed that CD4
+
 Treg cells abrogated CD8-mediated tumor rejection 
of HA
+
 CT44 cells  (M.-L. Chen et al.). In this cohort, tumor development of HA
+
 CT44 
cells closely mimicked the tumor development observed in CT26 tumor bearing mice 
(M.-L. Chen et al.). In contrast, adoptive transfer of HA specific CD8
+
 T cells and HA 
non-regulatory CD4
+
 T cells promoted tumor rejection of CT44 cells (M.-L. Chen et al.). 
This study highlights the role of CD4
+
 cells in enhancing CD8
+
 T cell immunity, while 
Treg cells interfere with CD
+
 T cell immunity.  
Taken together, these studies suggest that targeting the tumor cells alone may not be 
sufficient to effectively diminish tumor growth and that targeting the cells in the TME 
that provide a permissive environment for tumor re-growth is warranted for more 
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effective therapies. Modifying the TME may enhance response to therapy and improve 
the patient’s prognosis.  
1.6 MOUSE MODELS OF COLORECTAL CANCER 
Animal models have proven to be a reliable experimental tool to recapitulate the early 
and late stages of CRC. The Apc
Min/+
mouse has a germline mutation in the adenomatous 
polyposis coli (APC) gene that is similar to the mutation that is found in 80% of sporadic 
colon cancers in humans resulting in small intestinal and colonic tumors (A R Moser et 
al.; A. R. Moser et al.; Daniel et al.; Rowan et al.). Familial Adenomatous Polyposis 
(FAP) is an inherited form of colon cancer that is also a result of a mutation in the APC 
gene (Rowan et al.). In the murine model, the multiple intestinal neoplasia (MIN) mutant 
allele in the APC gene encodes a premature stop codon at 850 resulting in a truncated 
polypeptide that lacks among others, the beta-catenin (β-catenin) binding site (A. R. 
Moser et al.; Daniel et al.; Fearon and Vogelstein; Rowan et al.; A R Moser et al.). A 
mutant copy of the APC gene in mice predisposes them to spontaneous development of 
multiple adenomas residing predominantly in the small intestine and a few in the colon 
(A R Moser et al.; A. R. Moser et al.; Daniel et al.; Fearon and Vogelstein; Rowan et al.). 
The lifespan of the Apc
Min/+
mice is significantly reduced to approximately 15-20 weeks 
as a results of acute anemia and intestinal obstruction by tumors (A. R. Moser et al.; 
Daniel et al.; Fearon and Vogelstein; Rowan et al.; A R Moser et al.).  
Mechanistically, the APC gene encodes the tumor suppressor protein that acts as an 
antagonist to the WNT signaling pathway (Figure 1.4) (Zeisberger et al.). The APC 
protein is a member of the β-catenin destruction complex. β-catenin and the WNT 
signaling pathway regulate the maintenance, expansion, and differentiation of progenitor 
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cells. β-catenin specifically regulates the gene transcription of c-myc, an oncogene, and 
cyclin D, a regulator of cell cycle progression. When WNT signaling is inactive, the β-
catenin destruction complex binds and degrades β-catenin by targeting it for 
ubiquitination. Ubiquitinated β-catenin is sent to the proteasome to be further destroyed. 
This results in silencing of c-myc and cyclin D. However, WNT signaling is activated 
when WNT protein binds to its membrane-bound receptor, Frizzled. This binding results 
in the dissociation of the β-catenin destruction complex, and an increase in β-catenin 
levels in the cytoplasm due to evasion from degradation. β-catenin enters the nucleus and 
transcriptionally activates genes such as c-myc and cyclin D (Grumolato et al.; Polakis; 
Balkwill, Capasso and Hagemann; Novellasdemunt, Antas and Li). A mutation in the 
APC gene causes aberrant WNT signaling because the β-catenin destruction complex is 
no longer assemble due to the loss of β-catenin binding to APC. β-catenin escapes 
degradation causing elevated levels of β-catenin in the cytoplasm leading to its entry into 
the nucleus, which increases the transcription of c-myc and cyclin D. This occurs in the 
transit amplifying zone of the intestines and causes the cell to lose control of cell growth, 
differentiation, and survival which thereby permits polyps to form (Rennoll and Yochum; 
Polakis; Novellasdemunt, Antas and Li; Grumolato et al.).  
 
1.7 GOALS OF THE PROJECT 
The overall goal of this project is to understand the role of the gut microbiome in 
tumor development and response to 5-FU using the Apc
Min/+
mouse as a model of colon 
carcinogenesis. We will test the hypothesis that folic acid from the diet and gut 
microbiota modulates the response to 5-FU by modifying the gut microbiome 
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composition, the tumor immune microenvironment, and metabolic composition in the 
gut. In previous studies, Apc
Min/+
mice that were weaned to a folate deficient diet and 
maintained on the diet throughout their lifetime showed decreased tumor burden and 
improved response to 5-FU. However, given the significance of folate for healthy cellular 
function, administering and maintaining a folate deficient diet may be detrimental to a 
patient’s health. To develop a clinically relevant study, our goal is to determine if altering 
folate concentrations prior to and during chemotherapy by administering a folate 
deficient diet can enhance the efficacy of 5-FU therapy. We will use the Apc
Min/+
mice to 
test this hypothesis. The experimental design is shown in Figure 3.1. Tumor bearing mice 
were subjected to regular rodent chow, folate free, or folate replete diets and then 
subjected to systemic therapy with 5-FU. We harvested the small intestines and colon and 
assessed the tumor burden. Fecal pellets and blood were collected at several time points 
to determine changes in the gut microbiota and hematopoietic parameters in response to 
diet and 5-FU. We collected the cecum to assess changes in metabolites, such as short 
chain fatty acids (SCFAs), in response to diet and chemotherapy. Finally, we analyzed 





















Figure 1.1: 5-Year Survival Rate for Colorectal Cancer. 
Cancer patients are initially diagnosed a stage, which 
specifies the development and progression of their disease. 
As the stage increases from localized to distant, the 
severity of the disease increases which decreases the 
patient’s survival outcome. Patients diagnosed at stage one, 
where tumor growth is local to the originating tissue, have 
the highest chance of five-year survival at 90%. As tumors 
metastasize or establish in distance tissues, the chance of 
five-year survival drastically decreases to 10%. This figure 
highlights the importance of early detection and treatment 
strategies as well as the devastating effects of late stage 
CRC. Adapted from the NIH-NCI Surveillance, 
Epidemiology, and End Results Program (SEER), 

























Figure 1.2: 5-Fluorouracil and its Mechanism. 5-FU is the principal 
therapy used for patients with CRC. 5-FU functions as an antimetabolite 
drug where the C5 hydrogen molecule is replaced with a fluorine atom. 
Thymidylate synthase functions to convert dUMP to dTMP.  The 
addition of a fluorine atom renders thymidylate synthase ineffective and 
therefore inhibits the production of RNA and DNA. Adapted with 

























Figure 1.3: The Tumor Microenvironment. The TME is comprised of 
a heterogeneous population of cells. Tumors are infiltrated with host 
immune cells, cytokines, chemokines, and growth factors. These 
molecules together help the tumor to prosper and rapidly divide. The 
complexity of the TME makes it even more challenging to effectively 
target CRC so that one drug is not able to successfully kill all cells 
within the tumor. Adapted with permission from Quail and Joyce, 




























Figure 1.4: The WNT Signaling Pathway. The WNT signaling 
pathway is often compromised in CRC. The Apc
Min/+
 mouse contains a 
mutation in the Apc gene, which produces a pre-mature stop codon and 
a truncated protein. The Apc gene is a component of the β-catenin 
destruction complex which functions to sequester, ubiquitinate, and 
destroy β -catenin. The β - catenin destruction complex prevents β -
catenin from entering the nucleus to transcriptionally activate c-myc 
and cyclin D. A mutation in the Apc gene causes the dissociation of the 
β -catenin destruction complex and the release of β -catenin to enter the 
nucleus to activate transcription. During CRC, excess amounts of β -
catenin are entering the nucleus to drive cell cycle progression and 
promote tumorigenesis. Adapted with permission from Moon et al. 









Although 5-FU has been used in the clinical management of patients with CRC 
for many decades, it is only mildly effective in 10% of patients (Johnston and Kaye; 
Longley, Harkin and Johnston). As an added complication, the tumor is comprised of a 
heterogeneous population of both neoplastic and non-neoplastic cells which makes 
targeting the tumor cells challenging, and could increase the probability of tumor 
recurrence. Residual tumor cells left after surgery or therapy can grow and reconstitute 
the tumor, a major issue observed across numerous types of cancer. Therefore, effective 
targeting and complete removal of cancer cells within the tumor might require multiple 
treatments. Studies performed in patients and mice receiving a cocktail of therapies 
reported enhanced tumor regression and prolonged survival (O’Shaughnessy et al.; Nie et 
al.). In patients with advanced breast cancer receiving the combination therapy of 
docetaxel with capecitabine had a 35% decrease in disease progression (docetaxel 4.2 
months, docetaxel + capecitabine 6.1 months) (O’Shaughnessy et al.). In addition, 
patients receiving combination therapy had a significant 23% reduction in risk of death, 
and the mean survival increased from 11.5 months in patients receiving docetaxel alone 
to 14.5 months in patients receiving docetaxel and capecitabine (O’Shaughnessy et al.). 
Overall response rate improved from 30% to 42% when patients receiving combination 
therapy (O’Shaughnessy et al.). In addition, Nie et al. showed that treatment of balb/c 
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mice receiving a splenic injection of murine colorectal cancer cell line, CT26, with 
adeno-associated virus-hepatocyte growth factor kringle 1 domain (AAV-HGFK1) and 
recombinant adenovirus carrying p53 gene (Ad-p53) increased survival of mice and 
blocked local and distal tumor growth (Nie et al.). AAV-HGFK1 is an antagonist for 
hepatocyte growth factor (HGF) and interferes with angiogenesis (Nie et al.). Ad-p53 
permits gene transfer to p53 tumor suppressor gene into cells to sensitize cancer cells to 
treatment (Nie et al.). Adp53 has been shown to induce apoptosis and inhibit the growth 
of tumor cells (Nie et al.). Mice receiving the combination therapy of AAV-HGFk1 and 
Ad-p53 showed prolonged survival (63 days) compared to control untreated mice (21.5 
days; p< 0.01) (Nie et al.). Single treatment of AAV-HGFK1 or Ad-p53 mildly 
prolonged survival (AAV-HGFK1 27 days and Ad-p53 27.5 days, both P< 0.05) (Nie et 
al.). Combination therapy also blocked primary tumor growth (spleen) and metastatic 
spread (liver) as spleen and liver weights were significantly reduced in combination 
therapy recipient mice as compared to control untreated mice 20 days after splenic 
injection (P < 0.05) (Nie et al.). Subsequent studies indicate that this combination therapy 
blocks angiogenesis, endothelial cell migration, and cellular proliferation (Nie et al.).   
Tumors can also acquire resistance to 5-FU through many mechanisms. 
Thymidine can be salvaged through thymidine kinase which undermines the TS 
inhibition inflicted by 5-FU (N. Zhang et al.). Other mechanisms of resistance include 
over-expression of TS through gene amplification and elevated folate pools (N. Zhang et 
al.). These mechanisms of recurrence and resistance must be resolved in order to 
effectively treat patients. Supplementing 5-FU with other therapeutic targets may be a 
reliable method to enhance tumor response to treatment.  Specifically, targeting TS with 
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5-FU and removing folate, an essential cofactor, may render this enzyme ineffective, 
promote genetic instability within the tumor, and increase the cytotoxicity of 5-FU. 
In previous studies performed by Tucker et al. subjected three cohorts of Apc
Min/+
 
mice to different diets: Rodent Chow (RC), Folate Free (FF), and Folate Replete 
(FF+FA) (Tucker et al.). The FF and FF+FA diets contain 1% succinyl sulfathiazole 
(SST), an antibiotic that inhibits folate producing bacteria. Apc
Min/+
 mice were weaned at 
four weeks of age to RC, FF, or FF+FA. In cohort one, mice were treated with 5-FU (40 
mg/kg) or phosphate buffered saline (PBS) from four to nine weeks to determine the 
effect of dietary folate and 5-FU on tumor development. In cohort two, mice were treated 
with 5-FU or PBS from nine to 14 weeks to determine the effect of dietary folate and 5-
FU on established tumors. In cohort three, mice were treated with 5-FU and PBS from 
four to nine weeks, and then allowed to recover from 5-FU therapy until 15 weeks to 
determine the effect of dietary folate on tumor recurrence post-therapy. In each cohort, 
mice received three rounds of 5-FU (40mg/kg) or phosphate buffered saline (PBS) 
administered five days a week with one week of rest in-between treatments (Tucker et 
al.).  
Results from cohort one indicate that Apc
Min/+
mice fed the FF diet had a 
significant reduction in tumor burden at 10 weeks, while Apc
Min/+
 on the FF+FA diet 
showed a modest decrease in tumor burden as compared to mice on the RC diet. Mice on 
the FF diet had approximately a 50% reduction in tumor burden as compared to mice on 
the FF+FA diet. When mice were treated with 5-FU, there was a further reduction in 
tumor burden in mice on the FF diet as compared to mice on the RC or FF+FA diets 
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(Figure 2.1B) (Tucker et al.). These data suggested that a FF diet attenuated tumor 
growth and enhanced the cytotoxicity of 5-FU.    
Apc
Min/+
mice in cohort two received three rounds of chemotherapy starting at nine 
weeks and were euthanized at 15 weeks. These results showed that at 15 weeks, the 
tumor burden of mice fed the FF and FF+FA diets were more similar, and significantly 
lower as compared to mice fed the RC diet. When treated with 5-FU, mice on the FF diet 
showed the most significant reduction in tumor burden as compared to mice on the RC or 
FF+FA diets (Figure 2.1C) (Tucker et al.). These data suggested that although tumor 
burden was significantly diminished in mice fed the FF or FF+FA diets as compared to 
mice fed the RC diet, the difference in tumor burden between the two diets diminishes as 
tumors increased in size. However, when combined with 5-FU therapy, a FF diet 
enhanced therapeutic effects as indicated by reduced tumor burden.  
In cohort three, the effect of folate deficiency on tumor recurrence following 5-
FU therapy was determined. 5-FU was administered at four weeks of age. Following 
three rounds of chemotherapy, mice were given a six week recovery period and were 
euthanized at 15 weeks to assess tumor burden (Figure 2.2A). The results showed that 
tumor burden in mice on the RC and FF+FA diets that were given 5-FU rebounded to 
similar levels as those in control mice that were treated with PBS and never received 5-
FU (Figure 2.2B-C). In contrast, tumor burden in mice that were treated with 5-FU on the 
FF diet remained significantly lower as compared to untreated mice. These mice showed 
a 75% reduction in tumor burden compared to their age-matched littermates that had 
never received 5-FU (Figure 2.2D) (Tucker et al.). This data suggested that a FF diet 
suppressed tumor development even after the removal of 5-FU. Thus, 5-FU administered 
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under the RC and FF+FA diets appeared to be only cytostatic while administration in 
combination with the FF diet was more cytotoxic.  
In all of these studies, the FF and FF+FA diets contained 1% SST. Thus in 
addition to reduced folic acid (FA) levels in the diet, folate production by gut bacteria 
was also inhibited. Furthermore, this study only assessed the effect of the diets on 
circulating folate levels, but did not consider their effects on the gut microbiome 
composition or the potential role of the gut microbiota on tumor development or response 
to therapy. In addition, this study was conducted in mice up to 15 weeks of age.   
The overarching goal of this study is to determine the effect of folate deficiency 
and the role of the gut microbiome on tumor response to therapy. In this chapter, I will 
establish the baseline parameters with respect to tumor burden, blood parameters, and 
weights as well as collect pellets for analysis of changes in the gut microbiome when fed 
the different diets up to 18 weeks of age, when subsequent studies will be conducted.  
Thus, we conducted experiments as outlined in Figure 2.3. Apc
Min/+
 mice (38) 
were purchased from Jackson Laboratory (Bar Harbor, ME) at four weeks. Mice were 
immediately placed on RC, FF, and FF+FA diets. Fecal pellets and serum samples were 
collected every four weeks to assess changes in the gut microbiome and hematopoietic 
parameters. Mice were euthanized at 18 weeks to harvest essential organs for analysis 











mice typically display decreased body weight, enlarged spleens, and 
anemia as they succumb to CRC. Measurements of hematocrit (HCT), hemoglobin 
(HGB), and red blood cells (RBCs) typically provide a measure of the extent of anemia. I 
assessed these parameters to characterize the effects of folate deficiency on tumor 
development, progression, and overall health of the mice.  
The results showed that in general throughout the 18 weeks, Apc
Min/+
mice fed the 
FF diet displayed fewer symptoms of CRC as compared to mice on the RC and FF+FA 
diets. Mice fed the FF diet consistently had higher body weights as compared to mice fed 
the RC and FF+FA which consistently showed lower body weights. In fact, mice on the 
FF+FA diet succumbed to the disease rapidly as indicated by a steep decline in body 
weight starting at 12 weeks (Figure 2.4A). Due to their severe weight loss, mice on the 
FF+FA diet were euthanized pre-maturely at 15 weeks.  
An enlarged spleen is commonly observed in Apc
Min/+
mice with a high tumor 
burden. As CRC progresses and symptoms worsen, the spleen weight typically increases. 
Spleen weight was reduced significantly in mice fed the FF diet as compared to mice fed 
the RC and FF+FA diets. Replenishing FA, as observed in the FF+FA diet, caused 
enlargement of the similar to that observed in mice fed the RC diet. This suggested that 
FA may be a critical component in promoting systemic inflammation (Figure 2.5A).  
Mice fed the RC diet exhibited a steady decline in HCT, HGB, and RBCs starting 
at 12 weeks, a characteristic of Apc
Min/+
mice as they age. Mice fed the FF diet showed 
35 
improvement in hematopoietic parameters as compared to mice fed the RC diet, as they 
maintained healthy measures of HCT, HGB, and RBCs throughout the entire 18 weeks. 
On the other hand, mice on the FF+FA diet declined rapidly starting at seven weeks, just 
four weeks after being placed on the diet (Figure 2.5B-D). Although the hematopoietic 
parameters between RC and FF+FA mice were not similar, it was evident that 
replenishing the diet with folic acid had profound negative effects on systemic health. 
Overall, a FF diet reduced anemia, a major symptom of CRC in Apc
Min/+
mice.     
 
2.2B: FOLATE DEFICIENCY REDUCED TUMOR BURDEN 
 Tumor burden was assessed by counting the number of adenomatous polyps 
present in the small intestines and colon. Mice fed the RC and FF diets were euthanized 
at 18 weeks, while mice fed the FF+FA diet were euthanized at 15 weeks. Tumor burden 
was significantly reduced when mice were fed the defined diets, FF and FF+FA.  
However, the mice fed the FF and FF+FA at 18 and 16 weeks of age showed no 
significant difference in tumor burden (Figure 2.6A). In addition, tumor size was not 
significantly altered by the dietary alterations (Figure 2.6B). This data suggested that the 
defined diets suppressed tumor development in Apc
Min/+
 mice. Whether this suppression 
is due to the inhibition of bacterial folate production by SST or the defined diets is 
unknown and still needs to be determined. 
 
2.3 SUMMARY AND DISCUSSION 
The results from this study showed that a FF diet protected mice from typical 
CRC symptoms observed as tumor progress in Apc
Min/+
mice as indicated by an increase 
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in body weight, a decrease in spleen weight, and an improvement in hematopoietic 
parameters. When folic acid was added back into the diet, adverse effects were observed 
in the mice. Overall health of mice fed the FF+FA diet declined rapidly as indicated by a 
steep decrease in body weight, an increase in spleen weight, and a decrease in 
hematopoietic parameters. In fact, mice fed the FF+FA diet became very ill and had to be 
euthanized three weeks earlier (15 weeks of age), highlighting the negative systemic 
effects of elevated FA in Apc
Min/+
mice.  
Because tumor burden was assessed at a late stage in tumor development, the 
results showed no significant effect of FA on tumor burden in the defined diets. However, 
it is important to note that tumor burden was assessed at different times; due to the fact 
that mice fed the FF+FA diet had to be sacrificed earlier. In support of this notion, 
previous studies showed a reduction in tumor burden in mice on the FF diet, and a 
partially restored phenotype when FA was added back into the diet (Tucker et al.).  
However, these mice were euthanized at 10 weeks of age. When previous investigators 
assessed tumor burden at 15 weeks of age, they found that mice on FF and FF+FA diets 
showed a similar tumor burden. This data together suggests that a FF diet suppresses 
tumor development at early stages to tumorigenesis. However, as the mice continue to 
age and tumors continue to develop, the FF diet becomes less effective. Based on 
previous studies and experiments, tumor burden is unlikely to be changed if mice fed the 
FF+FA diet lived to the expected 18 weeks. Although restoring FA did not seem to 
significantly affect tumor burden, mice fed the FF+FA diet were very ill and anemic 
compared to mice fed the RC and FF diets.  
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In previous studies, Tucker et al. showed that tumor burden in 15 week old mice 
fed the FF and FF+FA diets were comparable suggesting that folate deficiency may not 
affect tumor initiation but may affect tumor progression (Tucker et al.). Our results 
suggest that at 18 weeks of age, tumors that were initiated in the mice fed the FF diet at 
four weeks eventually progress to the same size as those mice fed the FF+FA diet, even 
in the absence of folate from the gut microbiome that is inhibited by SST present in the 
diet. However, tumor burden in mice fed the FF and FF+FA diets were much lower than 























Figure 2.1: The Role of Folate on Tumor Development and Response to 
5-FU. Previous studies by Tucker et al. examined the role of folate deficiency 
in tumor response to 5-FU. Apc
Min/+
 mice were weaned to rodent chow, folate 
free or folate replete diets. A. Cohort one determined the impact of folate 
deficiency and 5-FU on tumor development whereas cohort two determined 
the impact of folate deficiency and 5-FU on the regression of tumors that are 
already established. Tumor burden in (B) cohort one and (C) cohort two 
showed that manipulating folate levels reduced tumor burden and treatment 
with 5-FU further reduced tumor burden. (* p< 0.05, ** p< 0.01, *** p< 
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Figure 2.2: The Role of Folate on Tumor Recurrence after Treatment 
with 5-FU. Previous studies by Tucker et al. examined the role of folate 
deficiency in response to 5-FU in Apc
Min/+
 mice that were weaned onto 
folate free and folate replete diets. A. Cohort three determined the impact of 
folate levels on tumor recurrence following the removal of 5-FU therapy. 
The results showed that tumor burden rebounded to untreated levels in 
Apc
Min/+
 mice fed the (B) rodent chow and (C) folate replete diets. 
However, the tumor burden in Apc
Min/+
 mice fed the (D) folate deficient diet 
remained low and similar to Apc
Min/+
 mice that received chemotherapy and 
were euthanized immediately after treatment. (* p< 0.05, ** p< 0.01, *** 
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Figure 2.3: Mouse and Spleen Weights and Hematopoietic Parameters. 
A. To establish a baseline for subsequent studies, Apc
Min/+
 mice were 
weaned onto rodent chow (RC), Folate Free (FF), and Folate Free plus 6 
ppm Folic Acid (FF+FA) diets. The FF and FF+FA diets contained 1% 
succinyl sulfathiazole (SST). Fecal pellets were collected at the designated 
time points. Mouse weights of Apc
Min/+
 mice fed the (B) RC (red), FF 
(purple), and FF+FA (blue) diets throughout the experiment and (C) at 
sacrifice. D. Spleen weights in Apc
Min/+
 mice fed the RC, FF, and FF+FA 
diets. Hematopoietic parameters, (E) hematocrit (HCT), (F) hemoglobin 
(HGB), and (G) red blood cells (RBCs), in Apc
Min/+
 mice fed the RC, FF, 
and FF+FA diets. Yellow bars indicate of the normal healthy range of these 




























Figure 2.4: Tumor Burden. Tumor burden was assessed by determining 
the number of polyps present in the small intestines and colon. A. Total 
tumor burden is reduced in Apc
Min/+
 mice fed the FF and FF+FA diets 
relative to mice fed the RC diet. B. Similar reduction in tumor burden 
was observed when we examined only tumors that are larger than 1mm. 






TRANSIENT MODIFICATIONS OF THE GUT MICROBIOTA THROUGH A 





Folate is an essential nutrient for a healthy individual. Reducing or eliminating 
folate can be detrimental to a healthy human and may lead to neoplastic transformation 
(Duthie). Folate is important for red blood cell formation as well as in the synthesis of 
amino acids and nucleotides. Folate plays a critical role in the catalysis by thymidylate 
synthase and is essential for DNA synthesis in actively proliferating cells. However, 
folate provides the essential co-factor required for TS function and its presence in the gut 
may enhance the cellular proliferation of tumor cells and therefore, may exacerbate CRC 
development and progression (Ryan and Weir). Eliminating folate in the gut during 
tumorigenesis may suppress tumor development and progression, and improve patient 
outcome. Because folate functions as a double-edged sword, manipulating its levels must 
be managed very carefully at the appropriate time. 
In previous studies (Tucker et al.) and in the previous chapter, mice were weaned 
to the different diets and kept on the diets throughout the study. To develop a clinically 
relevant strategy, my goal was to target the gut microbiota just prior to administration of 
chemotherapy to determine if folate depletion will render 5-FU more cytotoxic to tumors 
while protecting against drug induced toxicities. The experimental design that was used is 
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in Figure 3.1. Forty C57Bl/6 wild type (WT) and sixty Apc
Min/+
 littermates were 
purchased from Jackson Laboratory (Bar Harbor, ME) at four weeks of age. The mice 
were immediately placed on the RC diet upon arrival. Tumors were allowed to develop 
until the mice were 10 weeks of age. At 10 weeks, WT and Apc
Min/+
mice were randomly 
assigned to one of the following six experimental groups based on their diet and 
treatment: 1) Rodent Chow + PBS, 2) Rodent Chow + 5-FU, 3) Folate Free + PBS, 4) 
Folate Free + 5-FU, 5) Folate Replete + PBS, and 6) Folate Replete + 5-FU. Phosphate 
buffered saline (PBS) was used as the non-treatment control. Mice were maintained on 
their respective diets for three weeks to allow the gut microbiota to adapt to the diets. At 
13 weeks, mice were subjected to systemic treatment with 5-FU as described in Chapter 
2. Briefly, five doses/week of 5-FU (40mg/kg) or PBS were administered by 
intraperitoneal injection. Chemotherapy was administered for one week followed by a 
rest week, for a total of three rounds. Fecal pellets and sera were collected weekly 
throughout the experiment to assess changes in the gut microbiota and hematopoietic 
parameters. Mice were euthanized at 18 weeks and essential organs were harvested for 
analysis of tumor burden and immune cell infiltration. 
 
RESULTS 




 WT mice fed the RC diet maintained a relatively consistent body weight. When 
subjected to 5-FU, the mice lost weight after the treatment week but recovered during the 
rest week. Overall, the body weight of WT mice on the RC diet receiving 5-FU or PBS 
44 
did not fluctuate drastically and 5-FU treated mice recovered during the rest week 
suggesting no serious impact of 5-FU or PBS (Figure3.2A). WT mice fed the FF and 
FF+FA diets showed a gradual increase in body weight. Similar to mice fed the RC diet, 
mice on the FF and FF+FA diets lost weight when subjected to 5-FU but recovered 
during the rest week (Figure 3.2C,E). The diseased, Apc
Min/+
mice, responded quite 
differently. During three rounds of chemotherapy, the overall body weight of 
Apc
Min/+
mice was consistently lower than their WT counterparts as tumor development 
progressed. Apc
Min/+
mice fed the RC diet maintained a relatively consistent body weight 
when subjected to PBS and 5-FU (Figure3.2B). Apc
Min/+
 mice lost some weight during 
treatment with 5-FU but recovered during the rest week. However, Apc
Min/+
mice fed the 
FF and FF+FA diets showed a reduction in body weight over time as tumors develop in 
these mice. When subjected to 5-FU, these mice showed dramatic improvements in body 
weight (Figure3.2 D, F). In addition, Apc
Min/+
mice fed the FF diet showed the greatest 
increase in body weight and had fewer fluctuations in body weight than Apc
Min/+
mice fed 
the FF+FA diet. Specifically, Apc
Min/+
mice fed the FF+FA diet and treated with 5-FU 
reported large losses in body weight during treatment with chemotherapy (Figure 3.2D, 
F). 
The final body weights of mice at the end of the study provided an indication of 
the overall effects of CRC, diet, and 5-FU. WT mice fed the RC, FF, and FF+FA diets 
showed no significant difference in body weight at sacrifice (RC 28.45 ± 2.16, FF 29.40 
± 1.82, FF+FA 30.82 ± 3.82). However, following three rounds of chemotherapy, WT 
mice treated with 5-FU had lower body weights compared to their PBS treated controls 
(RC 5-FU 26.11 ± 1.49, FF 5-FU 25.66 ± 0.82, FF+FA 5-FU 25.10 ± 1.74) (Figure3.3A). 
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WT mice had consistently higher body weights relative to Apc
Min/+
littermates (WT RC 
28.45 ± 2.16 versus Apc
Min/+
 RC 24.25 ± 2.61; WT FF 29.40 ± 1.82 versus Apc
Min/+
 FF 
20.99 ± 2.48; WT FF+FA 30.82 ± 3.82 versus Apc
Min/+
 FF+FA 20.31 ± 2.38). The 
Apc
Min/+
mice fed the FF and FF+FA diets had significantly lower body weights as 
compared to mice fed the RC diet (RC 24.25 ± 2.61; FF 20.99 ± 2.48; FF+FA 20.31 ± 
1.28). However, when subjected to 5-FU, the body weights significantly increased in 
mice fed the FF and FF+FA diets, with mice fed the FF diet showing the highest body 
weight (RC 24.55 ± 1.55; FF 25.14 ± 1.35; FF+FA 23.57 ± 2.38) (Figure 3.3B).  
The average spleen weight was very small in WT mice fed the RC, FF, and 
FF+FA diets (RC .073 ± .0067; FF .078 ± .0110; FF+FA .0760 ± .0195) with a 
significant increase in RC but not FF and FF+FA diets when treated with 5-FU (RC .159 
± .0661, p=0.003; FF .102 ± .0753, p=0.52; FF+FA .126 ± .0907, p=0.29) (Figure 3.3C). 
On the other hand, the Apc
Min/+
mice had enlarged spleens (RC .500 ± .0822; FF .229 ± 
.1476; FF+FA .314 ± .1492). Apc
Min/+
mice fed the RC diet and treated with 5-FU showed 
a significant reduction in spleen weight as compared to untreated mice fed the RC diet 
(RC .289 ± .1199, p=0.0004). Interestingly, Apc
Min/+
mice fed the FF diet had smaller 
spleens that were not altered when treated with 5-FU (FF 5-FU .241 ± .0983, p=0.84). 
Lastly, the Apc
Min/+
 mice fed the FF+FA diet had a lower spleen weight as compared to 
Apc
Min/+
 mice fed the RC diet that increased when treated with 5-FU (FF+FA 5-FU .440 
± .1657; p=0.11) (Figure 3.3D). A decrease in the spleen weight among the Apc
Min/+
mice 
on a FF diet suggested reduced inflammation and potentially slowed disease progression 
that was further improved upon treatment with 5-FU. Interestingly, mice fed the FF+FA 
diet had lower spleen weights that were dramatically enlarged upon treatment with 5-FU. 
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As seen in chapter two, mice weaned to the FF+FA diet displayed enlarged spleens. This 
difference in weights may be due to the extended time that mice were fed the FF+FA diet 
in the previous study; that is, they were weaned to the diet at four weeks of age and kept 
on the diet until the end of the study. This data in the currently study perhaps suggests 
that FA may cause adverse effects in mice that are receiving 5-FU.  
As described in chapter two, hematopoietic parameters are useful tools to assess 
the presence of anemia in mice with developing CRC. The data showed that in WT mice 
on the RC diet, these parameters remained in the health range expected for HCT, HGB, 
and RBCs. When WT mice were fed the FF or FF+FA diet, these hematopoietic 
parameters also remained in the healthy range. However, when WT mice were treated 
with 5-FU, these parameters decreased but recovered to normal or healthy ranges by the 




 mice responded differently. Apc
Min/+
mice 
fed the RC diet showed a gradual decline in HCT, HGB, and RBCs throughout their 
lifetime. When treated with 5-FU, the mice exhibited healthy measures in these 
parameters following one round of 5-FU. Apc
Min/+
mice on FF and FF+FA diets showed a 
steeper decline in these hematopoietic parameters rendering these mice highly anemic. 
However, upon treatment with 5-FU, Apc
Min/+
mice on a FF diet quickly regained healthy 
ranges following one round of chemotherapy, similar to Apc
Min/+
mice fed the RC diet. 
The Apc
Min/+
mice on a FF+FA diet on the other hand, required three rounds of 
chemotherapy to recover to a healthy range in these hematopoietic parameters (Figure 
3.4A-C).  These data suggest that administering 5-FU in the presence of a FF diet 
improved the health of Apc
Min/+
mice, perhaps as a consequence of reduced tumor burden 
due to enhanced efficacy of 5-FU. In addition, Apc
Min/+
mice on the FF+FA diet required 
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three times the dosage of 5-FU before symptoms improved implying that FA in the diet 
hinders 5-FU from functioning effectively. These data also strongly correlates with a 
reduction in spleen weight observed in Apc
Min/+
 mice fed the FF diet and treated with 5-
FU and an increase in spleen weight in Apc
Min/+
mice fed the FF+FA diet and treated with 
5-FU.  
 
3.2B: FOLATE DEFICIENCY ENHANCED THE ANTI-TUMOR EFFICACY OF 5-FU 
Assessment of tumor burden after systemic 5-FU therapy of mice in the different 
diets revealed differences in tumor response to therapy. When Apc
Min/+
mice were 
switched to the FF or FF+FA diets at 10 weeks of age after tumors were established, 
there was no significant difference in tumor burden between mice fed the RC, FF, and 
FF+FA diets. The average tumor burden for mice fed the RC, FF, and FF+FA diets was 
statistically similar (RC 69.80 ± 18.66; FF 67.10 ± 27.36; FF+FA 60.44 ± 15.08) 
(Figure3.5D). When these mice were treated with 5-FU, the mice fed the RC and FF+FA 
diets exhibited a mild reduction in tumor burden of approximately 40% and 30% as 
compared to the untreated mice (RC 5-FU 44.60 ± 17.24, p=0.006; FF+FA 5-FU 42.20 ± 
21.27, p=0.045) (Figure3.5A-B). However, mice fed the FF diet and treated with 5-FU 
had a greater reduction in tumor burden by approximately 70% (FF 5-FU 22.40 ± 13.30, 
p=0.0005) (Figure3.5C). Compared to mice fed the RC and FF+FA diets, mice fed the FF 
diet showed a 50% greater reduction upon treatment with 5-FU (Figure 3.5E). This data 
strongly suggests that supplementing mice with a FF diet while receiving 5-FU was 
sufficient to enhance the anti-tumor efficacy of 5-FU. Therefore, under conditions where 
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dietary folate is diminished and folate production by the gut microbiota is inhibited, 5-FU 
is more potent at reducing tumor burden in Apc
Min/+
 mice.  
 
3.3 SUMMARY AND DISCUSSION 
 The results from this study showed that the effect of 5-FU on Apc
Min/+
 mice can 
be influenced by folate levels. Specifically, mice fed the FF diet and treated with 5-FU 
showed fewer fluctuations in body weight suggesting some protection against 5-FU 
toxicity while Apc
Min/+
mice fed the FF+FA diet and treated with 5-FU showed greater 
body weight loss. In addition, Apc
Min/+
mice fed the FF diet and treated with either PBS or 
5-FU had smaller spleens suggesting that removal of FA in the diet reduced systemic 
inflammation. Apc
Min/+
mice fed the FF+FA diet and treated with PBS also Hs smaller 
spleens; however, treatment with 5-FU caused enlargement of the spleen. This 
observation may suggest that SST may function to suppress systemic inflammation in 
Apc
Min/+
mice fed the FF and FF+FA diets; however, upon treatment with 5-FU, mice fed 
the FF diet were protected against 5-FU toxicity, but restoring folate into the diet 
exacerbated 5-FU effects. The data also showed that FA supplementation with 5-FU 
promoted inflammation, which was consistent with the effects on the hematopoietic 
parameters. In the data analyzing HCT, HGB, and RBCs, Apc
Min/+
mice on the FF and 
FF+FA diets and treated with PBS became anemic. A FF diet alone was not sufficient to 
reduce anemia in Apc
Min/+
mice; however, when treated with 5-FU, mice fed the FF diet 
were able to regain healthy levels of all three hematopoietic markers after only one round 
of 5-FU. The mice fed the FF+FA diet on the other hand, required three rounds of 5-FU 
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to regain healthy levels of HCT, HGB, and RBCs. These results suggest that a FF diet 
can protect against hematopoietic toxicity from 5-FU.  
The improved hematopoietic parameters in Apc
Min/+
mice fed the FF diet 
correlated with decreased tumor burden. Control mice on RC, FF, and FF+FA diets 
treated with PBS showed no significant differences in tumor burden. This data is 
suggestive that the tumors were established at 10 weeks of age, altering the diet did not 
impact tumor progression. However, upon treatment with 5-FU, mice that were fed the 
FF diet showed a much larger reduction in tumor burden as compared to mice that were 
fed the RC or FF+FA diets.    
The results further showed that altering the gut microbiota did not impact the 
development of already established tumors. Control mice on the FF and FF+FA diets had 
similar body and spleen weights, and hematopoietic parameters. Despite this, there were 
striking differences in their response to 5-FU. The results thus far have shown that folate 
deficiency and 5-FU together protects against weight loss, alleviates inflammation as 
indicated by a reduced spleen weight, protects against hematopoietic toxicity, and 
reduces tumor burden. In the next chapter, we will examine the potential mechanisms 




















Figure 3.1: Experimental Design for the Role of Folate on 5-
Fluorouracil in Apc
Min/+
 Mice. This diagram shows the timeline for the 
experiment to determine the impact of folate deficiency on the anti-tumor 
efficacy of 5-FU in Apc
Min/+
 mice. WT and Apc
Min/+
 mice were purchased 
from Jackson Laboratory. Upon arrival at our facility, mice were placed 
on the RC diet. At 10 weeks, mice were randomly assigned to RC, FF, or 
FF+FA diets. At 13 weeks, mice started their three rounds of 5-FU or 
PBS systemic therapy with a rest week in between the treatment weeks. 
Fecal pellets were collected as indicated below and mice were euthanized 
















Figure 3.2: Mouse Weight throughout 5-FU Exposure. The impact of 5-
FU was assessed by monitoring the body weight throughout treatment. 
Results showed changes in the body weights of WT mice fed the (A) RC, 
(C) FF, and (E) FF+FA diets treated with PBS and 5-FU. These results also 
show changes in body weight of Apc
Min/+
 mice fed the (B) RC, (D) FF, and 






















 Figure 3.3: Mouse and Spleen Weight. Mouse weight of (A) C57Bl/6 WT 
and (B) Apc
Min/+
 mice fed the RC, FF, and FF+FA diets and treated with 
PBS (blue) or 5-FU (red). Spleen weight of (C) C57Bl/6 and (D) Apc
Min/+
 
mice fed the RC, FF, and FF+FA diets and treated with PBS (blue) or 5-FU 





















Figure 3.4: Hematopoietic Parameters. The levels of Hematocrit (HCT), 
hemoglobin (HGB), and red blood cells (RBCs) in mice fed the (A) RC, (B) 
FF, (C) FF+FA diets throughout the experiment. Results in the WT mice are 
indicated by solid lines and Apc
Min/+
 mice are indicated by dashed lines. Blue 
lines are representative of PBS treated mice and red lines are indicative of 5-
FU treated mice. The yellow bars are indicative of the normal healthy range 
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Figure 3.5: Tumor Burden. A-C Tumor burden in Apc
Min/+
 mice fed the (A) 
RC, (B) FF, and (C) FF+FA diets treated with PBS (blue) and 5-FU (red). 
Tumor burden in Apc
Min/+
 mice fed the RC, FF, and FF+FA diets and treated 
with (D) PBS and (E) 5-FU. (* p< 0.05, ** p< 0.01, *** p< 0.001, ns not 





A FOLATE DEFICIENTCY ALTERS THE GUT MICROBIOTA AND PROMOTES 
TUMOR REGRESSION
4.1 INTRODUCTION 
The results from chapter three suggest that a folate deficiency can enhance the 
cytotoxic effects of 5-FU. We hypothesized that a potential underlying mechanism might 
be that the FF diet with 1% SST might alter the gut microbiota to create a less 
inflammatory microenvironment that might facilitate tumor suppression and regression. 
Previous studies have shown that the gut microbiota is altered in CRC to promote and 
exacerbate tumorigenesis (Rubinstein et al.; Kostic, Chun, et al.; Castellarin et al.; Kostic, 
Gevers, et al.; Zackular, Baxter, Iverson, et al.; Zackular, Baxter, Chen, et al.). In 
addition, previous studies have also shown that the gut microbiota may determine the 
efficacy and toxicity of chemotherapy suggesting that targeting and manipulating the gut 
microbiota may be a powerful tool to enhance therapeutic efficacy against CRC (Yu et 
al.; Levy et al.; Scott et al.; Soveri et al.; Alexander et al.; Iida et al.). The gut microbiota 
is comprised of numerous bacterial species, some of which may be beneficial or harmful. 
It is important to identify which gut microbial populations are changing in response to 
diet to elucidate how these microorganisms may promote or suppress tumor development 
or therapeutic efficacy.  
Therefore, the goal of this chapter is to determine the changes in the gut microbial 
populations as a consequence of dietary manipulation. Identifying the bacterial 
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populations and species that are altered might provide insight into cellular and molecular 
events occurring at the tumor microenvironment.  
To determine the gut microbiome composition, we isolated genomic DNA from 
fecal pellets at different time points in the study. To assess changes in the gut microbiota 
in response to diet, our analysis will include WT mice fed the RC diet and Apc
Min/+
 mice 
fed the RC, FF, and FF+FA diets. 
We hypothesized that changing the diets from RC to FF or FF+FA might alter the 
gut microbiota to enhance 5-FU efficacy and cytotoxicity to tumors. Genomic DNA 
isolated from fecal pellets was prepared for 16S ribosomal sequencing using Next 
Generation Sequencing (NGS). Samples were sent to the Heflin Genomics Core at the 
University of Alabama, Birmingham. R1 and R2 FastQ files were retrieved and analyzed 
using Quantitative Insights Into Microbial Ecology (QIIME) Analysis Software.  
 
RESULTS 
4.2A: A FOLATE DEFICIENT DIET WITH 1% SST SIGNIFICANTLY ALTERED 
THE GUT MICROBIOME COMPOSITION 
16S ribosomal sequencing revealed significant changes in the gut microbiome 
composition in response to dietary manipulation. Alpha diversity is a statistical analysis 
indicating the microbial diversity present within a sample. It provides valuable 
information regarding species richness, or the number of species present within a sample, 
and species evenness, or the relative abundance of different species within a sample. A 
rarefaction plot shows the number of species as a function of the number of samples and 
is a powerful tool to assess species richness. The major characteristic of a rarefaction 
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curves is a steep initial slope that eventually plateaus. This steep initial slope represents 
of the most common species that are present while the plateau represents the rare species 
within the sample. A rarefaction plot that plateaus early suggests that a particular sample 
has less species richness. The rarefaction plot (Figure 4.1B) shows that WT and 
Apc
Min/+
mice fed the RC diet both had high species richness. When mice were switched 
to the defined diets, FF and FF+FA, there was a significant decrease in species richness. 
The rarefaction plots were quantified to show the number of observed operational 
taxonomic units (OTUs) within each sample (Figure 4.1A). This data showed that WT 
and Apc
Min/+
 mice fed the RC diet had no significant difference in species richness 
suggesting that CRC does not significantly impact the number of species present within a 
sample. However, when mice are switched to the FF and FF+FA diets, the number of 
species present within the samples significantly decreases suggesting that the diets are 
largely responsible for species richness and altering the abundance of microbes in the gut. 
Beta diversity is a descriptive interpretation that shows the diversity of a set of 
samples to other samples within the dataset. In microbiome datasets, beta diversity is 
often summarized in a principal component analysis (PCoA) plot, which transforms a 
number of correlated variables into a small number of uncorrelated variables. PCoA plots 
are typically two or three-dimensional where each dimension accounts for a principal 
component. The first principal component usually accounts of the most variability within 
the data and the subsequent principal components account for the remaining variability 
present in the dataset. PCoA plots can also be unweighted or weighted. An unweighted 
PCoA plot is a qualitative interpretation that only accounts for the absence or presence of 
species whereas the weighted PCoA plot is a quantitative interpretation that accounts for 
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the relative abundance of species. The four groups used in this analysis were WT mice 
fed the RC diet, and Apc
Min/+
 mice fed the RC, FF, and FF+FA diets.  In the unweighted 
PCoA plot, there is clear separation between all four groups suggesting that the microbes 
present in the gut were distinct from each other. This data strongly suggests that WT and 
Apc
Min/+
mice have significant differences in the composition of microbes present in their 
gut. In addition, this data also shows that the FF and FF+FA diets dramatically altered the 
species present in the gut microbiota (Figure 4.1C). In the weighted PCoA plot, where the 
abundance of bacterial species is accounted for, there was no clear separation between the 
groups suggesting that the relative abundance of specific taxa is not driving this effect 
(Figure 4.1D).   
When analyzing gross compositional shifts at the phylum level, there was a 
significant expansion of Firmicutes and reduction of Bacteroidetes in Apc
Min/+
mice fed 
the FF and FF+FA diets (Figure 4.2A). The ratio of Bacteroidetes to Firmicutes 
significantly decreased in Apc
Min/+
mice fed the FF and FF+FA diets as compared to WT 
and Apc
Min/+
mice fed the RC diet (Anova P=0.04) (Figure 4.2B). When analyzing the 
gross compositional changes at the family level, there was a significant loss of the 
Bacteroidetes S24-7 group in mice fed the FF and FF+FA diets. Furthermore, in mice fed 
the FF and FF+FA diets, there was an expansion in members of the Firmicutes family 
Ruminococcus, and an unclassified family within Clostridiales class (Figure 4.2C; Figure 
4.3D-E). The S24-7 family population was significantly diminished, and the 
Coriobacteriaceae family and Lactobacillus genus populations expanded in mice fed the 
FF and FF+FA diets (Figure 4.3A-C). It is interesting to note that these changes in the gut 
microbiome composition occurred in mice fed the FF and FF+FA diets, despite the 
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addition of folate in the FF+FA diet suggesting that these may be a result of the defined 
diets or the presence of the antibiotic, SST. It would be interesting to determine if such 
changes will occur in the absence of the antibiotic.  
Although many changes were found Apc
Min/+
mice fed the FF and FF+FA diets, 
there were some changes observed only in Apc
Min/+
mice fed the FF diet. When folate was 
reconstituted in the FF+FA diet, some bacterial populations were present at similar 
abundances as compared to Apc
Min/+
 mice fed the RC diet. Apc
Min/+
mice fed the RC and 
FF+FA diets showed low levels of the Firmicutes family, Ruminococcus sp., and an 
unclassified family within the Costridiales class. However, Apc
Min/+
mice fed the FF diet 
had higher levels of these populations (Figure4.3 D-E). This data suggests that although 
the majority of changes observed in the gut microbiota are driven by the FF and FF+FA 
diets, FA in the diet still modifies some bacterial populations in the gut.  
 
4.3 SUMMARY AND DISCUSSION 
The results from these studies examining the impact of diet on the gut 
microbiome composition revealed vast differences in alpha and beta diversity. Mice fed 
the FF and FF+FA diets showed a significant reduction in species richness and diversity. 
The unweighted PCoA plot showed a clear distinction amongst the four experimental 




 FF, and Apc
Min/+
 FF+FA, suggesting that the 
differences were primarily driven by the species present within the communities among 
the different cohorts. In addition, the weighted PCoA plot, which accounts for the relative 
abundance of each taxa within the communities, displayed no separation among the four 
groups. This suggests that the differences were not driven by the relative abundance of 
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specific taxa. These principal component plots strongly suggest that perhaps the microbes 
populating the gut, as a consequence of diet may play a major role in tumor response to 
therapy. The weighted PCoA plot highlights how the abundance of microbes populating 
the gut is not playing a role in tumor response to therapy. In support of this notion, the 
Bacteroidetes S24-7 population was nearly eliminated in Apc
Min/+
 mice fed the FF and 
FF+FA diets, an effect that is unique and novel.  
The S24-7 family is an unculturable family belonging to the Bacteroidetes 
phylum that has recently gained attention in the field. This bacterial group is generally 
present in 20% of humans and 50% of mice. Genomic characterization reveals that S24-7 
is generally a beneficial group of bacteria, although some members down regulate the 
immune system. They are capable of producing anti-inflammatory short chain fatty acids 
(SCFAs) acetic acid, propionic acid, and succinic acid as well as folate, thiamine, 
riboflavin, niacin, pantothenate, and biotin. In addition, evidence shows that S24-7 
contains proteins to provide protection against oxidative stress. Finally, it is known that 
some members of the S24-7 family metabolize host glycans which can potentially impact 
gut inflammation by influencing gut permeability (Ormerod, Wood, Lachner, Gellatly, 
Daly, Parsons, Dal’Molin, et al.). Perhaps, the diverse functions of S24-7 may influence 
the concentration of SCFAs in the gut and reduce the abundance of folate in the gut. In 
addition, perhaps the reduction in S24-7 in mice fed the FF and FF+FA diets may 
increase oxidative stress to tumor cells to promote cell death. Depletion of S24-7 may 
also aid in reducing gut inflammation and permeability.   
Changes in the gut microbiota can have a potent impact on the concentration of 
metabolites and the infiltration of immune cells into the TME. Of particular interest, the 
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Bacteroidetes phylum produces a variety of short chain fatty acids (SCFAs) including 
acetic acid, propionic acid, succinic acid, and small amounts of butyric acid (Ormerod, 
Wood, Lachner, Gellatly, Daly, Parsons, Dal'Molin, et al.; den Besten et al.; Louis and 
Flint; Adamberg et al.; Finegold et al.; Ren et al.). In addition, members of the Firmicutes 
phylum produce butyric acid and small amounts of propionic acid (Donohoe et al. "A 
Gnotobiotic Mouse Model Demonstrates That Dietary Fiber Protects against Colorectal 
Tumorigenesis in a Microbiota- and Butyrate-Dependent Manner"; den Besten et al.; 
Louis and Flint; Revuelta et al.). SCFAs have different functions in the gut including 
energy sources for the gut microbiota and intestinal epithelial cells, inhibitors of histone 
deacetylases (HDACs), ligands for G protein-coupled receptors (GPCRs), and the 
activation  and expansion of immune cells (Rooks and Garrett). It is possible that loss of 
the Bacteroidetes S24-7 population or expansion of the Firmicutes families may promote 
changes in the metabolite concentrations in the gut. These may further have an impact on 
the recruitment of immune cells into the TME. The results from these studies suggest that 
assessing the changes in metabolite concentrations and the TME composition are critical 


























Figure 4.1: Alpha and Beta Diversity. Alpha diversity by (A) 
observed OTUs (Operational Taxonomic units) and (B) rarefaction plot 
of WT mice fed the RC diet and Apc
Min/+
 mice fed the RC, FF, and 
FF+FA diets. Beta diversity (C) unweighted and (D) weighted 
principal component plots of WT mice fed the RC diet and Apc
Min/+
 








































Figure 4.2: Alterations in the Bacterial Phylum and Family in Response 
to Diet. A. Phylum compositional changes in WT mice fed the RC diet and 
Apc
Min/+
 mice fed the RC, FF, and FF+FA diets. B. The ratio of 
Bacteroidetes to Firmicutes in WT and Apc
Min/+
 mice fed the RC, FF, and 
FF+FA diets. C. Changes in microbial family composition in WT mice fed 
the RC diet and Apc
Min/+




























Figure 4.3: Most Altered Microbes in the Gut in Response to Dietary 
Changes. Changes in the abundance of (A) S24-7, (B) Coriobactericeae, (C) 
Lactobacillus, (D) Ruminococcus sp., and (E) Clostridiales in Apc
Min/+
 mice fed 
the RC, FF, and FF+FA diets. (* p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 





A FOLATE DEFICIENCY PROMOTES CHANGES IN GUT METABOLITE 
CONCENTRATIONS
5.1 INTRODUCTION 
 Alterations to the gut microbiota can yield significant changes in the 
concentration of metabolites present in the gut (den Besten et al.; Louis, Hold and Flint; 
Tremaroli and Bäckhed). These include short chain fatty acids (SCFAs) which constitute 
a large group of volatile metabolites produced in the gut through fermentation of 
carbohydrates by anaerobic bacteria (den Besten et al.). SCFAs can function as inhibitors 
of histone deacetylase (HDAC), an enzyme that can regulate gene expression but is also 
known to drive the expansion and activation of hematopoietic and non-hematopoietic 
cells. This inhibitory action of SCFAs regulates immune homeostasis and promotes the 
establishment of a tolerant anti-inflammatory cell phenotype (den Besten et al.; Donohoe 
et al. "A Gnotobiotic Mouse Model Demonstrates That Dietary Fiber Protects against 
Colorectal Tumorigenesis in a Microbiota- and Butyrate–Dependent Manner"; Louis, 
Hold and Flint; Ríos-Covián et al.; Rooks and Garrett; Vinolo et al.). In addition, studies 
have shown that SCFAs can inactivate Nuclear Factor - κβ (NF-κβ) and TNF-α in 
peripheral blood monocytes and neutrophils (Vinolo et al.). NF-κβ is a transcription 
factor that stimulates cytokine production and cell survival, while TNF-α is a cytokine 
that stimulates cell growth and differentiation (Usami et al.; Vinolo et al.). Specifically, 
propionic and butyric acids have both been shown to upregulate FoxP3 expression and 
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Treg cell differentiation to influence homeostasis and attenuation of colitis in mice 
(Rooks and Garrett; Tao et al.). SCFAs have also been shown to function as ligands for 
GPCRs (Sun et al.). GPCRs are expressed on the cell surface of a variety of cells 
including colonic cells, colonic mast cells, neutrophils, eosinophils, and Treg cells, 
peripheral mononuclear cells, apical membrane of colonic epithelium, macrophages, 
monocytes, and dendritic cells (DCs) (Donohoe et al. "A Gnotobiotic Mouse Model 
Demonstrates That Dietary Fiber Protects against Colorectal Tumorigenesis in a 
Microbiota- and Butyrate-Dependent Manner"; W. Wu et al.; Ohira, Tsutsui and Fujioka; 
Sun et al.). In addition to the diverse expression of these GPCRs, their physiological 
functions range from mediating increased energy expenditure, hematopoiesis of DCs 
from bone marrow, expansion of t-regulatory cells and macrophages, protection from 
irritable bowel disease (IBD) and colitis, and promoting IgA response (Ohira, Tsutsui and 
Fujioka; W. Wu et al.; den Besten et al.). Together these data show the powerful impact 
of SCFAs and their anti-inflammatory effects in the gut microenvironment. Although 
numerous lines of evidence suggest that SCFAs are beneficial to human health and 
disease, their role in CRC has not been fully established. However, it is known that 
immune-tolerance and immune-suppression by Treg cells is detrimental in CRC because 
Treg cells inhibit the cytotoxic function of CD8
+
 T cells and prevent tumor cell death 
(Antony et al.). Perhaps SCFAs produced by the gut microbiota may influence 
homeostasis and increase the activation and infiltration of Treg cells during 
tumorigenesis. However, under circumstances of tumorigenesis, inflammatory responses 
that activate cytotoxic CD8+ T cells are preferred to effectively target and destroy the 
tumor. It may be possible to alter the concentrations of SCFAs in the gut to influence the 
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activation and infiltration of immune cells that will promote tumor cell death (Louis, 
Hold and Flint). To further increase the complexity, the diverse ecosystem of gut 
microbes and metabolites makes understanding the direct effect of one specific 
metabolite in a system, where multiple shifts are occurring, challenging. 
 The goal in chapter five is to determine how SCFA concentrations in the gut are 
altered as a consequence of CRC, diet modifications, and 5-FU treatment. Identifying 
which SCFAs are altered may provide insight into how a FF diet in combination with 5-
FU promotes tumor suppression and 5-FU cytotoxicity. Folic acid is a co-factor that is 
required for the formation of acetic, propionic, and butyric acids which are the most 
abundant SCFAs present in the gut (Louis and Flint). Thus it is possible that SCFAs may 
be altered in response to folate deficiency.   
 To determine the changes in SCFA levels, the cecum of WT and Apc
Min/+
mice 
was analyzed. For each mouse strain, the following six groups (diet and treatment) were 
processed: Rodent Chow + PBS, Rodent Chow + 5-FU, Folate Free + PBS, Folate Free + 
5-FU, Folate Replete + PBS, and Folate Replete + 5-FU. The following six SCFAs were 
analyzed: acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, and 
valeric acid. 2-ethyl butyric acid was used as the internal control. Approximately 50 mg 
of cecal content was weighed and processed as described in chapter 8. SCFAs were 
extracted into methyl tert-butyl ether (MTBE) and analyzed using gas chromatography – 
flame ionization detection (GC-FID). Peaks were detected and the area under the curve 





 Analysis from GC-FID indicated significant changes in the concentrations of the 
different metabolites in response to CRC, dietary manipulation, and 5-FU. However, the 
data showed the largest changes in SCFAs when mice were switched from the RC diet to 
the defined FF and FF+FA diets. Although the results suggested that folate was not the 
primary driver for changes in the SCFA concentrations, the data typically showed a 
partially restored phenotype when folate was added back into the FF diet. This implied 
that there are changes in SCFA concentrations that might have occurred in response to 
folate levels and changing into the defined diets. It is unclear whether the composition of 
SCFAs was impacted by the defined diets or the presence of 1% SST. In addition, it is 
important to mention that WT mice showed consistent changes in SCFA levels in 
response to diet and 5-FU whereas Apc
Min/+
 mice showed fluctuations that may be in part 
due to the tumor burden in Apc
Min/+
mice. In this section, the changes in SCFA levels will 
be described in both WT and Apc
Min/+
 mice that have been subjected to dietary 
manipulations and 5-FU.  
 
ACETIC ACID 
 Acetic acid, or ethanoic acid, is a two carbon SCFA that is highly abundant in 
mice (Ríos-Covián et al.). Although the role of acetic acid has not been fully established, 
it is known that acetic acid functions to inhibit enteropathogens, or disease causing 
bacteria in the gut. The data showed that the concentrations of acetic acid were 
significantly altered during CRC, dietary manipulation, and treatment 5-FU. WT mice fed 
the RC diet reported elevated levels of acetic acid. Treatment with 5-FU caused a 
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significant reduction in acetic acid concentrations (RC PBS 3.33 ± 1.12 versus RC 5-FU 
1.57 ± 0.58, p=0.02). When WT mice were switch to FF or FF+FA diets, acetic acid 
levels decreased significantly as compared to mice fed the RC diet (FF PBS 0.331 ± 0.24, 
p=0.004; FF+FA PBS 1.55 ± 0.7, p=0.019). When subjected to 5-FU, acetic acid levels 
remained low and were statistically similar as compared to untreated WT mice fed the FF 
and FF+FA diets (FF 5-FU 0.43 ±  0.40, p= 0.58; FF+FA 5-FU 1.15 ±  1.05, p=0.49 ). 
Furthermore, the acetic acid level observed in WT mice fed the FF were partially restored 
to that in mice fed the RC diet when folic acid was added back into the diet. 
Apc
Min/+
mice, on the other hand, had low levels of acetic acid when fed the RC, FF, and 
FF+FA diets as compared to WT mice fed the RC diet (RC PBS 1.41 ± 0.73; FF PBS 
0.39 ± 0.75; FF+FA PBS 0.71 ± 0.46). There was no statistical difference between mice 
fed the RC diet and mice fed the FF (p= 0.09) or FF+FA (p=0.12) diets. When treated 
with 5-FU, Apc
Min/+
mice fed the RC diet had increased levels of acetic acid as compared 
to untreated control mice (RC 5-FU 4.352 ± 1.35, p=0.0052) whereas Apc
Min/+
mice fed 
the FF and FF+FA diets remained at reduced levels (FF 5-FU 0.48 ± 0.23; FF+FA 5-FU 
0.56 ± 0.42). There was no statistical difference between untreated mice fed the FF or 
FF+FA diet as compared to 5-FU treated mice fed the FF (p=0.87) and the FF+FA 
(p=0.73) diets.   
Although the concentration of acetic acid remained low in mice fed the FF and 
FF+FA diets during treatment with PBS or 5-FU, it is interesting to note that the presence  
of tumors in Apc
Min/+
 mice modified the levels of acetic acid present in the gut. WT mice 
fed the RC diet had higher levels of acetic acid whereas Apc
Min/+
mice fed the RC diet did 




 mice these levels increased. These results suggest that 5-FU in a WT 
mouse may initiate inflammation and that 5-FU in a diseased mouse may alleviate 
inflammatory conditions. Apc
Min/+
 mice exhibited decreased levels of this anti-
inflammatory SCFA regardless of diet. Perhaps treatment with 5-FU during CRC helps to 
reduce inflammation and tumor progression. Our data showed that administering a FF or 
FF+FA diet reduced levels of acetic acid in both WT and Apc
Min/+
 mice, and restored 
levels when FA was added back into the diet in WT mice. Although it is difficult to 
determine fully, it appears that folic acid in the diet stimulated the production of acetic 
acid. In addition, the defined diets or 1% SST alone may suppress the gut microbes that 
are responsible for acetic acid formation. Further studies are necessary to delineate the 
impact of the defined diets and the presence of 1% SST.      
 
PROPIONIC AND BUTYRIC ACID 
 Propionic acid, or ethanecarboxylic acid, is a three carbon SCFA and butyric acid, 
or propanecarboxylic acid is a four carbon SCFA (Ríos-Covián et al.). Propionic and 
butyric acid together with acetic acid are the SCFAs that have been studied immensely. 
Propionic acid is only mildly abundant in the gut of mice whereas butyric acid is highly 
abundant. Propionic and butyric acid have many similarities and overlap in function. 
Butyrate and propionate are known to induce the differentiation of Treg cells and regulate 
intestinal inflammation through the inhibition of HDACs. HDAC is an enzyme that 
facilitates winding of DNA around histones to inactivate gene expression (Tao et al.). 
Butyrate and propionate have numerous other functions that make these SCFAs 
important aspects in obesity, colitis, and CRC (Louis, Hold and Flint).  
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CRC, dietary manipulation, and treatment with 5-FU have significant effects on 
propionic and butyric acid concentration in the cecum. WT mice fed the RC diet had 
elevated levels of both SCFAs that are significantly reduced when subjected to 5-FU 
(Propionic Acid: RC PBS 0.68 ± 0.15 versus RC 5-FU 0.43 ± 0.14; p=0.027) (Butyric 
Acid: RC PBS 2.053 ± 0.49 versus RC 5-FU 1.32 ± 0.57; p=0.004). WT mice fed the FF 
and FF+FA diets had reduced levels of propionic and butyric acid as compared to WT 
mice fed the RC diet (Propionic Acid: FF PBS 0.041 ± 0.03, p=0.0008; FF+FA PBS 0.16 
± 0.038, p=0.0018) (Butyric Acid: FF PBS 0.61 ± 0.21, p=0.0001; FF+FA PBS 0.90 ± 
0.32, p=0.0001). These levels remained low during treatment with 5-FU (Propionic Acid: 
FF 5-FU 0.05 ± 0.02; FF+FA 5-FU 0.04 ± 0.03) (Butyric Acid: FF 5-FU .78 ± 0.26; 
FF+FA 5-FU 0.70 ± 0.40). However, there was a significant difference in propionic acid 
levels between WT mice fed the FF+FA diet treated with PBS and 5-FU (P = 0.0019). 
Similar to acetic acid, the elevated levels of propionic and butyric acid, observed in WT 
mice fed the RC diet, were partially restored when folic acid was added back into the 
diet. This suggested that folic acid in the diet may contribute to the production of these 
SCFAs. In contrast, Apc
Min/+
mice fed the RC diet had lower levels of propionic and 
butyric acid that were elevated during treatment with 5-FU (Propionic Acid: RC PBS 
0.40 ± 0.22 versus RC 5-FU 0.65 ± 0.12; p=0.06) (Butyric Acid: RC PBS 1.14 ± 0.55 
versus RC 5-FU 2.92 ± 1.12; p=0.0004). Similar to the WT mice, Apc
Min/+
mice fed the FF 
and FF+FA diets had reduced levels of these SCFAs as compared to Apc
Min/+
 mice fed 
the RC diet (Propionic Acid: FF PBS 0.04 ± 0.04, p=0.022; FF+FA PBS 0.10 ± 0.04, 
p=0.037) (Butyric Acid: FF PBS 0.55 ± 0.52, p=0.17; FF+FA PBS 0.48 ± 0.24, p=0.16). 
These levels remained low during treatment with 5-FU (Propionic Acid: FF 5-FU 0.09 ± 
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0.069; FF+FA 5-FU 0.04 ± 0.03) (Butyric Acid: FF 5-FU 0.59 ± 0.28; FF+FA 5-FU 0.51 
± 0.21). However, there was a significant reduction in propionic and butyric acid levels 
between 5-FU treated Apc
Min/+
 mice fed the RC diet and 5-FU treated Apc
Min/+
 mice fed 
the FF (Propionic Acid: p=0.0001; Butyric Acid: p=0.0001) or the FF+FA (Propionic 
Acid: p=0.0004; Butyric Acid: p=0.0001) diets. Propionic acid levels were slightly 
elevated in Apc
Min/+
mice fed the FF+FA diet suggesting partial restoration of SCFA 
levels, although there was still a significant difference between Apc
Min/+
 mice fed the RC 
and FF+FA diets (p=0.0004). Perhaps these changes have implications on the TME that 
impact tumor regression and rejection in response to therapy.  
Similar to the data with acetic acid, CRC modified the concentration of propionic 
and butyric acid when mice are fed the RC diet. However, the FF and FF+FA diets 
suppressed the levels of propionic and butyric acid which may be due to the defined diets, 
folate deficiency, or inhibitor of folate production, 1% SST.  In addition, the restoration 
of the SCFAs upon addition of FA to the FF diet was only observed with propionic acid 
but not butyric acid. The restoration was clearly observed in WT mice, but not the 
Apc
Min/+
mice which may be due to their exacerbated diseased state as a factor 
contributing to their unique response. Examining the modifications in SCFAs in WT 
mice helped to establish the base line effects of diet on SCFA levels in the cecum.  
 
5.3 SUMMARY AND DISCUSSION 
 This data showed specific changes in the composition of SCFAs that were a direct 
result of CRC, dietary alterations, and 5-FU treatment. Most of the SCFA levels that were 
lower in the presence of a FF diet were partially restored when FA was added back into 
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the diet (FF+FA) indicating that FA in the diet has an impact on SCFA production in gut 
metabolism and CRC disease progression. Acetic, propionic, and butyric acids are the 
most abundant SCFAs present in the gut and are of particular interest because they all 
play a role in immune activation and differentiation. We postulate that SCFAs may play a 
role in modulating the TME as they are localized in the tumor and therefore can have 
direct implications on the recruitment of immune cells into the TME. Future studies 
where Apc
Min/+
mice are supplemented with individual SCFAs may indicate which SCFAs 




























Figure 5.1: Short Chain Fatty Acid Composition. Changes in the 
abundance of (A) acetic, (B) propionic, and (C) butyric acid in WT and 
Apc
Min/+
 mice fed the RC, FF, and FF+FA diets that were treated with PBS 





A FOLATE DEFICIENCY PROMOTES CHANGES IN THE TUMOR 
MICROENVIRONMENT
6.1 INTRODUCTION 
 Previous chapters have shown that a FF diet in combination with 5-FU enhanced 
the efficacy of anti-tumor therapy using 5-FU. Mice receiving this combination therapy 
showed a lower tumor burden and systemic improvement based on spleen and mouse 
weight, as well as hematopoietic parameters. These results may be a consequence of the 
FF diet modifying the gut microbiota, causing a depletion of the Bacteroidetes S24-7 
population and an expansion of the Firmicutes Ruminococcus and Clostridiales 
populations. These alterations may in turn affect the concentration of SCFAs in the gut. 
In particular, our data showed a significant reduction in acetic, propionic, and butyric 
acids when mice were fed the FF and FF+FA diets with partial restoration in the FF+FA 
diet when folate was added back. However, the diets were both folate deficient and also 
inhibited folate production by the gut microbiota. Thus it is important to delineate these 
two components to determine their impact on tumor response to therapy.  It is known that 
these SCFAs have potent implications of the activation and recruitment of immune cells 
into the TME. Based on what is known, we hypothesize that a FF diet and 5-FU together 
promote tumor cytotoxicity through manipulating the TME. To further determine the 
mechanism underlying the enhanced 5-FU, we will characterize the immune cells 
infiltrating the TME. Studies have shown that the TME plays a key role in the treatment 
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of cancers (Peddareddigari, Wang and DuBois; Trédan et al.; Quail and Joyce; M.-L. 
Chen et al.; Miselis et al.; Lin, Li, et al.; Lin, Nguyen, et al.; O'Callaghan et al.; 
Zeisberger et al.; Gounaris et al.; Maltby, Khazaie and McNagny; Kitadai et al.; 
Crawford et al.; Francia, Emmenegger and Kerbel; Ryan et al.; Yasuhiko et al.). For 
example, there is evidence showing that host-tumor interactions can facilitate pro-
tumorigenic and anti-tumorigenic immune responses. We hypothesize that innate immune 
cells like myeloid-derived suppressor cells (MDSCs), mast cells, and macrophages 
infiltrate the tumor to create an inflammatory environment that promotes tumorigenesis. 
In addition, we hypothesize that adaptive immune cells, such as Treg cells and cytotoxic 
T cells, have opposing effects on CRC development. Treg cells, which function to 
regulate and control inflammatory responses, are thought to have a negative impact on 
tumor regression by suppressing the immune responses to tumorigenesis. On the other 
hand, cytotoxic T cells are thought to promote tumor regression by destroying cancer 
cells. It is unknown how 5-FU administered with a FF diet can modulate the TME. 
Determining which immune cells are infiltrate the TME may help to elucidate their 
function and provide insight into the mechanism underlying the enhanced cytotoxicity of 
5-FU. 
 In addition to assessing the infiltration of these cells into the TME, it is also 
important to determine their circulating levels to assess the systemic effects of dietary 
manipulation and 5-FU treatment. As previously discussed, the effects of a FF diet and 5-
FU therapy are systemic and local to the TME. Our data showed that the combination 
therapy has systemic effects as determined by an increase in mouse body weight, 
decrease in spleen weight, and improvement of hematopoietic parameters. However, our 
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data also showed that the combination therapy also exerts its effects locally through 
alterations in the gut microbiome composition that may lead to changes in SCFA 
concentrations, and a decrease in tumor burden. Incorporating the circulating levels of 
immune cells into the analysis will provide evidence of the systemic effects of combined 
therapy that will supplement the local TME analysis.   
Therefore, the goal in chapter six is to determine how the TME and systemic 
microenvironment are affected by a FF diet and 5-FU. Identifying which immune cell 
populations are present, absent, or modified may provide insight as to how the TME 
facilitates tumor cytotoxicity of Apc
Min/+
 mice. 
To study the changes in the TME, six experimental groups were analyzed (diet 
and treatment): Rodent Chow + PBS, Rodent Chow + 5-FU, Folate Free + PBS, Folate 
Free + 5-FU, Folate Replete + PBS, and Folate Replete + 5-FU. Three mice from each 
group were selected and three tumors were imaged per mouse tissue to yield a total of 
nine tumors per group. Tissues were embedded in 13% acrylamide and cut 200 µm thick 
using a tissue vibratome. Tissues were stained with conjugated antibodies against cell 
surface markers for mast cells (CD117+ and FcEr1a+), macrophages (F4/80+), 
granulocytes (Gr1+), T-regulatory cells (Treg cells) (CD4+ and FoxP3+), and cytotoxic T 
cells (CD8+). Stained tissue sections were imaged using the Zeiss LSM 510 META 
Confocal Scanning Laser Microscope at the University of South Carolina, School of 
Medicine. Images were taken at 20x magnification and the entire region of each tumor 
was imaged. Immune cells were counted to determine the total number of a particular 
immune cell present within the tumor.     
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 To assess changes in circulating levels of immune cells, peripheral blood was 
collected from the retroorbital sinus of  mice at four time points: prior to 5-FU 
administration, after administration of the first round of 5-FU, after one week of rest in 
between 5-FU administration, and at sacrifice. The same experimental groups used above 
were analyzed. To establish the baseline circulating immune cell levels, peripheral blood 
obtained prior to 5-FU administration was collected after the mice had been transferred to 
their new diets for three weeks prior to receiving any chemotherapy. 75 µL of blood was 
processed for flow cytometry to detect mast cells, macrophages, and MDSCs. Data 
collected from flow cytometry represents the percentage of each particular immune cell 
present in a given sample.   
 
RESULTS 
6.2A: A FOLATE DEFICIENT DIET AND 5-FU MODULATE THE TUMOR 
MICROENVIRONMENT 
Analysis of the tumor sections indicated that several changes in the cellular 
composition of the TME occurred as a result of dietary manipulation and 5-FU treatment. 
The data showed that the greatest changes occurred when mice were transferred from the 
RC to the defined FF and FF+FA diets. In this section, we assessed the number of 
immune cells including mast cells, macrophages, granulocytes, Treg cells and cytotoxic T 
cells in tissues from mice receiving different diets and/or 5-FU therapy.  The number of 
cells was normalized against the tumor size. We found that normalizing had no 
significant effect on the amount of immune cell infiltration, suggesting that the size of the 




Mast cells are members of the innate immune system and play a major role in 
protection against pathogens and parasites (Marshall). Mast cells can secrete 
inflammatory mediators, attract other inflammatory immune cell populations, and 
promote tissue repair; however, the behavior of the mast cell depends heavily on the 
extrinsic signal received (Maciel, Moura and Hermine). Mast cells also play a role in 
angiogenesis, immune tolerance, defense against pathogens, and wound healing (Aponte-
López et al.; Maciel, Moura and Hermine). Mast cells have had a controversial role in 
tumor development and progression. Conflicting data have implicated that mast cell 
accumulation in tumors as either beneficial or harmful to tumor development and 
progression (Aponte-López et al.; Maciel, Moura and Hermine). Other data have shown 
conflicting correlations with metastasis, patient survival, and prognosis (Aponte-López et 
al.; Maciel, Moura and Hermine). However, a larger amount of data implicates mast cells 
as being pro-tumorigenic because they are capable of initiating angiogenesis and tissue 
remodeling (Aponte-López et al.; Maciel, Moura and Hermine).  
Apc
Min/+
mice fed the FF and FF+FA diets had similar levels of mast cell 
infiltration which was significantly lower as compared to mice fed the RC diet (RC PBS 
17.42 ± 8.649; FF PBS 9.70 ± 8.11, p=0.044; FF+FA PBS 9.10 ± 9.398, p=0.046). 
Adding back FA did not significantly alter the levels of mast cells in mice fed the FF+FA 
diet as compared to mice fed the FF diet (p=0.88) (Figure 6.1A). Thus, infiltrating mast 
cells are not impacted by folate levels in the diet. When subjected to 5-FU, mice fed the 
RC diet showed a significant reduction in infiltrating mast cells that were similar to the 
80 
level of mast cells infiltrates in mice fed FF diet treated with PBS or 5-FU (RC 5-FU 7.70 
± 6.13, p=0.0062). Interestingly, when FA was restored to the FF+FA diet, there was an 
increase in the infiltration of mast cells into the TME when mice were treated with 5-FU 
(FF+FA 5-FU 14.29 ± 4.92). This data suggests that the FF+FA diet combined with 5-FU 
creates an inflammatory TME through the enhanced recruitment of mast cells. This data 
suggests that mast cells may be a key immune cell that is responsible for altering the 
TME and facilitating a pro-tumorigenic microenvironment when folate is present. 
However, mice fed the RC and FF+FA diets had different levels of mast cell infiltration, 
suggesting that FA alone was not the sole mechanism of this enhanced inflammation.  
 
MACROPHAGES 
Macrophages are members of the innate immune response and play a major role 
in phagocytosis, non-specific defense mechanisms, and activation of adaptive-specific 
defense (Martinez and Gordon). Specifically, macrophages are essential for T cell 
activation. They are classified into pro-inflammatory M1and anti-inflammatory M2 
macrophages (Martinez and Gordon). In addition, tumor associated macrophages (TAMs) 
belong to both M1 and M2 subtypes and have been shown to be involved in cancer-
promoting inflammation and suppression of T-cell anti-tumor immunity (Ostuni et al.). 
Although macrophages have a dual function, they are commonly perceived as 
contributors to tumor development and therefore are associated with poor prognosis 
across a variety of cancers (L., J. and E.; J. J. W. Chen et al.; DeNardo et al.; Di Caro et 
al.; Steidl et al.).    
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Macrophages were significantly reduced in Apc
Min/+ 
mice fed the FF and FF+FA 
diets as compared to their levels in mice fed the RC diet (RC PBS 49.50 ± 28.35; FF PBS 
5.818 ± 4.47, p=0.0001; FF+FA PBS 9.85 ± 11.17, p=0.0002). However, there was no 
significant difference in macrophage infiltration between mice fed the FF and FF+FA 
diets suggesting that macrophages are not impacted by FA levels (p=0.17) (Figure 6.1B). 
When subject to 5-FU, mice fed the RC diet had a significant reduction in macrophages 
as compared to the PBS treated controls (RC 5-FU 27.36 ± 14.78, p=0.0204). 
Macrophage infiltration was also slightly elevated in mice fed the FF and FF+FA diets 
that were treated with 5-FU as compared to the PBS treated controls; however, these 
were not statistically significant (FF 5-FU 16.88 ± 13.72, p=0.059; FF+FA 5-FU 18.45 ± 
11.17, p=0.054). In addition, there was no statistical difference in macrophage infiltration 
between mice fed the RC, FF, or FF+FA diets that were treated with 5-FU although there 
was a slight reduction in mice fed the FF and FF+FA diets. Although we are able to 
determine the general pattern and changes in immune infiltration, further characterization 
of the macrophages, as M1 and M2 macrophages, will be needed to determine if their 
function as pro-inflammatory or anti-inflammatory.  
 
MDSCs 
MDSCs are a heterogeneous population of immunosuppressive myeloid cells that 
inhibit T cell differentiation (De Sanctis et al.). Expansion of MDSCs occurs during 
chronic inflammatory conditions such as cancer and leads to angiogenesis and tumor 
progression (De Sanctis et al.). Cancer patients with a high infiltration of MDSCs in the 
TME typically have poor prognosis (Gabrilovich and Nagaraj). Because of their negative 
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impact on immune-stimulation, MDSCs have become a critical focus in cancer research. 





however, in this study we will use the Gr1
+
 marker to assess the MDSC population.  
The results from this study showed that granulocytes are significantly reduced in 
the TME of mice fed the FF and FF+FA diets as compared to mice fed the RC diet (RC 
PBS 32.00 ± 18.57; FF PBS 3.89 ± 3.90, p=0.0003; FF+FA PBS 7.67 ± 4.98, p=0.0009). 
Although granulocytes were slightly higher in mice fed the FF+FA diet as compared to 
mice fed the FF diet, the data was not statistically significant (p=0.069) (Figure 6.C). 
When subjected to 5-FU, mice fed the RC diet showed a slight increase in granulocyte 
infiltration as compared to the PBS treated controls; however, this was not statistically 
significant (RC 5-FU 37.30 ± 25.10; p=0.59) . Mice fed the FF and FF+FA diets that 
were treated with 5-FU showed enhanced infiltration of granulocytes as compared to the 
PBS treated controls, but this did not reach the levels detected in mice fed the RC diet 
(FF 5-FU 12.82 ± 9.86, p=0.017; FF+FA 5-FU 19.50 ± 9.09, p=0.0084). MDSCs are 
typically considered as negative prognostic markers in CRC, therefore, a reduction in 
MDSCs in mice fed the FF and FF+FA diets may help to reduce tumor development and 
improve response to therapy. In addition, a reduction in MDSCs in the TME may slow 





 T cells are categorized into T helper (Th) cells and T-regulatory (Treg) 
cells. Treg cells are members of the adaptive immune system and have been shown to 
play a major role in tolerance and suppression of the immune system, particularly tumor-
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specific CD8 T cells (M.-L. Chen et al.; Corthay; Mougiakakos et al.; Takeuchi and 
Nishikawa). In addition, Treg cells are important for autoimmunity and protection from 
commensal bacteria (Corthay; Mougiakakos et al.; Takeuchi and Nishikawa). The role of 
Treg cells in cancer has become complicated due to their functional diversity (Corthay; 
M.-L. Chen et al.; Curiel; Mougiakakos et al.; Takeuchi and Nishikawa). Treg cells are 
elevated in patients with cancer and hinder the effects of therapy and thus, correlate with 
poor patient survival (Curiel; Mougiakakos et al.; Takeuchi and Nishikawa). In support of 
this notion, Treg cells play a role in immunoediting where they stimulate immune 




 cells in the tumor 
promotes tumor rejection (Quezada et al.). Controlling the amount of infiltrating Treg 
cells may improve patient prognosis. Due to the complexity and significance of Treg cells 
in cancer, we determined if folate plays a role in Treg cell accumulation in the TME.  
The results from our studies showed that immune infiltration of Treg cells was 
significantly reduced in mice fed the FF and FF+FA diets as compared to mice fed the 
RC diet (RC PBS 48.67 ± 18.16; FF PBS 14.56 ± 8.06, p= 0.0001; FF+FA PBS 21.27 ± 
23.78, p=0.0064). In addition, there was no significant difference in Treg cell infiltration 
between mice fed the FF and FF+FA diets (p=0.40) (Figure 6.1D). When subjected to 5-
FU, mice fed the RC diet had a significant reduction in Treg cell infiltration into the TME 
as compared to untreated controls whereas mice fed the FF and FF+FA diets showed no 
significant change (RC 5-FU 18.00 ± 7.86, p=0.0001; FF 5-FU 9.143 ± 7.86, p=0.20; 
FF+FA 5-FU 20.50 ± 9.12, p=0.92). Because Treg cells are known to induce immune 
tolerance, the elimination of Treg cells in the tumor bed may provide a beneficial 
advantage to mice fed the FF and FF+FA diets. Consistent with these results, upon 
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treatment with 5-FU Treg cells remained at low levels in mice fed the FF and FF+FA 
diets as compared to mice fed the RC diet where Tregs were significantly reduced.  
Overall, the results indicate that both the FF and FF+FA diets facilitate an anti-
tumorigenic TME before treatment with 5-FU. Furthermore, a FF diet further suppresses 
Treg infiltration when mice are treated with 5-FU suggesting that the combined effect of 
no dietary folate and inhibition of folate producing bacteria is the most beneficial to the 
mice.  
 
CYTOTOXIC T CELLS 
 Cytotoxic T cells are members of the adaptive immune response and play a major 
role in destruction of damaged, infected, and cancerous cells (Gajewski, Schreiber and 
Fu; Bennett et al.). T-cells are activated by innate antigen presenting cells and CD4 Th 
cells to facilitate T-cell specific killing.  Cytotoxic T cells are essential to anti-tumor 
immunity and elevated levels of cytotoxic T cells promote tumor regression and patient 
survival (Naito et al.; Phan et al.; Tosolini et al.). High infiltration of cytotoxic T cells 
would therefore aid in destroying the tumor. Because of the beneficial properties for 
cytotoxic T cells, we determined their abundance in the TME of the mice in the 
experimental groups.  
 The results from this study showed that cytotoxic T cells are significantly reduced 
in the TME of mice fed the FF and FF+FA diets as compared to mice fed the RC diet 
(RC PBS 25.09 ± 16.14; FF PBS 4.00 ± 5.37, p=0.0017; FF+FA PBS 4.00 ± 6.28, 
p=0.0018). However, there was no significant difference in cytotoxic T cell infiltration in 
the TME between mice fed the FF and FF+FA diets (p=1.00). When subjected to 5-FU, 
85 
mice fed the RC diet had a significant reduction in cytotoxic T cell infiltration into the 
TME as compared to untreated controls whereas mice fed the FF and FF+FA diets 
showed no significant changes (RC 5-FU 0.77 ± 1.17, p=0.0006; FF 5-FU 1.00 ± 0.82, 
p=0.052; FF+FA 5-FU 3.80 ± 4.96, p=0.94).   
 These results suggest that the defined diets or SST may be contributing to 
alterations in the recruitment of cytotoxic T cells into the TME.  However, since 
cytotoxic T cells are beneficial in suppressing tumor development, perhaps cytotoxic T 
cells may not be responsible for the enhanced cytotoxicity of 5-FU in mice fed the FF 
diet. Furthermore, cytotoxic T cells were significantly reduced upon treatment with 5-FU, 
This is consistent with the previous data in the literature where repeated treatments of 5-
FU caused a depletion and impairment of cytotoxic T cell function (Y. Wu et al.).  
 
6.2B: A FOLATE DEFICIENT DIET AND 5-FU MODULATE CIRCULATING 
LEVELS OF IMMUNE CELLS  
 Analysis by flow cytometry showed that circulating levels of immune cells were 
altered during treatment with 5-FU rather than diet modifications. In this section, we 
assessed the numbers of circulating mast cells, macrophages, and MDSCs in WT and 
Apc
Min/+
mice that were fed the different diets and were treated or not with 5-FU.   
 
MAST CELLS 
 As described above, mast cells are innate immune responders that play a major 
role in angiogenesis, immune tolerance, and protection (Aponte-López et al.; Maciel, 
Moura and Hermine). WT mice fed the RC, FF, and FF+FA diets had low levels of 
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circulating mast cells; while the mice fed the FF and FF+FA diets showed a gradual 
increase in mast cells over time. This did not rise to the level of significance. When 
subjected to 5-FU, WT mice fed the FF diet showed an increase in circulating levels of 
mast cells whereas mice fed the RC and FF+FA diets did not. These elevated levels were 
reduced by the time of sacrifice. Overall, the largest change in mast cell infiltration was 
observed in WT mice fed the RC diet and treated with 5-FU (WT: RC PBS 0.63 ± 0.10 
versus RC 5-FU 1.60 ± 0.42, p=0.02) (Figure6.2A-D).  
Apc
Min/+
mice on the RC diet had relatively similar levels of circulating mast cells 
as compared to the WT mice, that increased steadily throughout their lifetime. 
Apc
Min/+
mice fed the FF and FF+FA diets had reduced levels of mast cells after treatment 
with PBS. Following PBS treatment, mast cell levels in mice fed the FF diet increased 
while those in mice fed the FF+FA diet fluctuated until the time of sacrifice. When 
subjected to 5-FU, there was no significant change in mast cell levels in mice fed the RC 
diet. However, in mice fed the FF and FF+FA diets, mast cell levels were immediately 
reduced after 5-FU treatment, followed by a significant increase after the rest week. Mast 
cell levels remained high in mice fed the FF diet similar to the PBS treated controls at the 
time of sacrifice and partially normalized in mice fed the FF+FA diet similar to the PBS 
treated controls by the time of sacrifice. Overall, there were no significant changes in the 
circulating levels of mast cells in Apc
Min/+
mice at sacrifice (Figure 6.2E-H). 
This data shows that mice fed the FF diet have elevated circulating levels of mast 
cells upon treatment with 5-FU and that these levels remain elevated until the time of 
sacrifice. These data suggest that mast cell differentiation and production is affected by 5-
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FU in the Apc
Min/+
mice and perhaps a FF diet may contribute to the enhanced activation 
of mast cells.  
 
MACROPHAGES 
 Macrophages are innate immune responders that play a major role in T cell 
activation as well as phagocytosis and non-specific host defense (Ostuni et al.; Martinez 
and Gordon). The circulating levels of mast cells in WT mice fed the RC, FF, and FF+FA 
diets remained at steady levels throughout their lifetime. When subjected to 5-FU, 
macrophages in WT mice fed the RC diet were rapidly diminished; however, they 
returned to pre-treatment levels during the rest week. On the other hand, circulating 
levels of macrophages in WT mice fed the FF diet were quickly diminished following 
treatment with 5-FU, but recovered to pretreatment levels. Similarly, circulating levels of 
mast cells in WT mice on the FF+FA diet were reduced by 5-FU treatment, and partially 
recovered to the pre-treatment levels after the rest week. Overall, circulating macrophage 
levels in mice fed the FF and FF+FA diets that were treated with 5-FU were lower 
relative to the mice that were fed the RC diet. Although 5-FU caused a reduction in 
circulating mast cell levels in all mice on the different diets, the largest reduction was 
observed in WT mice on the FF+FA diet (WT: FF+FA PBS 7.125 ± 0.85 versus FF+FA 
5-FU 1.20 ± 0.28, p=0.0009 ) (Figure6.3 A-D). 
Macrophage levels n Apc
Min/+
mice fed the RC and FF+FA diets showed a 
continued decrease over the experimental period while levels stayed constant in 
Apc
Min/+
mice on the FF diet. Treatment with 5-FU reduced the circulating macrophage 




mice are fed the RC and particularly the FF diets and treated with 5-
FU as compared to Apc
Min/+
mice fed the FF+FA diet, whose levels increased after the rest 
week. Overall, macrophage levels are most reduced in Apc
Min/+
mice fed the FF diet and 
treated with 5-FU (Figure 6.3 E-H).  
These data showed that in mice fed the FF diet, circulating levels of macrophages 
are significantly diminished and remain at low levels upon treatment with 5-FU. Their 
loss may play an important role in tumor rebound after 5-FU treatment.   
 
MDSCs 
 MDSCs are a heterogeneous population of immunosuppressive myeloid cells that 
inhibit T cell differentiation. WT mice fed the RC, FF, and FF+FA diets had low levels 
of circulating MDSCs. Treatment with 5-FU caused a significant reduction in circulating 
MDSCs that recovers after a rest week (Figure 6.4 A-C). Because MDSCs only expand 
during inflammation, WT mice had similar levels of circulating MDSCs regardless of 
diet that significantly decreased during treatment with 5-FU. The most significant 
changes in circulating MDSC levels was in response to treatment with 5-FU across all 
three diets wherein there was a significant reduction in their levels (Figure 6.4A-D).  
 Apc
Min/+
 mice on the RC diet had fluctuating levels of circulating MDSCs. 
reported elevated levels of MDSCs that became reduced during treatments with PBS. At 
the time of sacrifice, Apc
Min/+
mice fed the RC diet had elevated levels of circulating 
MDSCs as compared to Apc
Min/+
mice fed the FF and FF+FA diets, who had reduced 
levels of circulating MDSCs. Upon treatment with 5-FU, circulating levels of MDSCs in 
Apc
Min/+
mice fed the RC, FF, and FF+FA diets were significantly reduced, however, they 
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recovered to near pre-treatment levels during the rest week. Overall, Apc
Min/+
 mice fed the 
RC, FF, and FF+FA diet show decreased levels of circulating MDSCs as compared to 
PBS treated controls; however Apc
Min/+
 mice fed the FF diet showed the most significant 
reduction in MDSCs after treatment with 5-FU as compared to PBS treated controls (FF 
PBS 25.70 ± 2.26 versus FF 5-FU 9.30 ± 2.24, p=0.0001) (Figure 6.4E-H).  
Collectively, these data showed that treatment with 5-FU causes a significant 
reduction in circulating MDSC levels that was further enhanced when Apc
Min/+
mice are 
fed the FF diet, where their levels remained low. This potentially contributes to the 
enhanced response and tumor cytotoxicity observed in these mice. Elimination of folate 
in the diet may minimize the recovery of MDSCs and may help to keep the immune 
system in check, preventing tumor growth.  
  
6.3 SUMMARY AND DISCUSSION 
Together, these results indicate that the TME is significantly altered when mice 
are fed the FF and FF+FA diets. Mice fed the RC diet showed an abundant infiltration of 
the TME by all of the immune cells examined. When these mice were subjected to 5-FU, 
the infiltration of mast cells, macrophages, Treg cells, and cytotoxic T cells was 
significantly reduced. However, in mice fed the FF and FF+FA diets, there was a 
significant reduction in the infiltration of the TME by all the immune cell populations 
including, mast cells, macrophages, granulocytes, Treg cells, and cytotoxic T cells as 
compared to mice fed the RC diet. In addition, treatment with 5-FU in mice fed the FF 
and FF+FA diets did not affect the infiltration of these immune cell populations. These 
data suggest that diminishing the number of immune cells that are infiltrating the TME 
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may create an anti-tumorigenic TME that causes the tumors to be more susceptible to 5-
FU therapy in mice fed the FF and FF+FA diets.  
Although these results did not show that the diet impacts the circulating levels of 
mast cells, macrophages, or MDSCs, these results did show that circulating levels these 
immune cell populations were impacted by CRC and 5-FU. In addition, treatment of 
Apc
Min/+
 mice with 5-FU caused a reduction of mast cells, macrophages, and MDSCs; 
however, Apc
Min/+
 mice fed the FF diet had the most significant reduction in MDSCs. 
Because MDSCs can be detrimental to tumor progression and recurrence.it is important 
to manage the circulating levels of these immune cells. The reduction in circulating 
MDSCs in mice fed the FF diet also correlated with the reduction of MDSCs in the TME 
suggesting that the FF diet may help prevent the activation and expansion of MDSCs into 
the TME. Removing MDSCs, an immune cell population that plays a significant role in 
cytotoxic T cell suppression, may enhance the cytotoxicity of 5-FU. In addition, Treg 
cells were also significantly reduced in the TME when Apc
Min/+
 mice were fed the FF diet 
and these levels remained reduced during treatment with 5-FU. Blocking the infiltration 
of an immunosuppressive cell that promotes immune regulation and tolerance like Treg 
cells is essential to enhance tumor regression through cytotoxic T cells. These data 
suggest that the FF diet in combination with 5-FU therapy shifts the tumor-immune 
response from pro-tumorigenic to anti-tumorigenic.  
When examining the circulating levels before and after treatment, after rest, and at 
the time of sacrifice, Apc
Min/+
 mice fed the FF+FA diet that were treated with 5-FU 
showed the largest fluctuations in mast cells, macrophages, and MDSCs as compared to 
Apc
Min/+
 mice fed the RC or FF diets that were treated with 5-FU. These results suggest 
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that the FF+FA diet may enhance inflammation and cause adverse effects systemically. 
These results are consistent with the increased anemia observed in Apc
Min/+
 mice fed the 
FF+FA diets that had an enlarged spleen and required three rounds of 5-FU therapy to 
achieve healthy levels of HCT, HGB, and RBCs. Apc
Min/+
 mice fed the FF diet on the 
other hand only required one round of 5-FU therapy to achieve healthy levels of HCT, 
HGB, and RBCs.  
Although this data showed how CRC, dietary modifications, and treatment with 
5-FU altered the circulating levels and recruitment of immune cells into the TME, it is 
essential to determine the molecular mechanisms that are influencing these changes. 
Because our results suggest that MDSCs and Treg cells are playing a major role in tumor 
response to 5-FU therapy, future studies will determine how a FF diet prevents the 
infiltration of these populations into the TME. Our results suggest that the gut 
microbiome is responsible for these changes; therefore, repeating these studies using a 
GF mouse model will help establish how specific microbes are influencing the activation 


























Figure 6.1: Recruitment of Bone Marrow Derived Cells into the Tumor 
Microenvironment. The total counts of (A) mast cells, (B) macrophages, 
(C) granulocytes, (D) t-regulatory cells, and (E) cytotoxic T cells into the 
TME of Apc
Min/+
 mice fed the RC, FF, and FF+FA diets that were treated 
with PBS (blue) or 5-FU (red). (* p< 0.05, ** p< 0.01, *** p< 0.001, ns not 


























Figure 6.2: Circulating Levels of Mast Cells. The circulating levels of mast 
cells before initial treatment with 5-FU, after treatment with 5-FU, after the 
rest week, and at sacrifice in WT mice fed the (A) RC, (B) FF, and (C) FF+FA 
diets and in Apc
Min/+
 mice fed the (E) RC, (F) FF, and (G) FF+FA diets.  Blue 
represents PBS treated mice and red represents 5-FU treated mice. Bar graphs 
represent the total percentage of mast cells at sacrifice in (D) WT and (H) 
Apc
Min/+


























Figure 6.3: Circulating Levels of Macrophages.  The circulating levels of 
macrophages before initial treatment with 5-FU, after treatment with 5-FU, 
after the rest week, and at sacrifice in WT mice fed the (A) RC, (B) FF, and (C) 
FF+FA diets and in Apc
Min/+
 mice fed the (E) RC, (F) FF, and (G) FF+FA diets.  
Blue represents PBS treated mice and red represents 5-FU treated mice. Bar 
graphs represent the total percentage of mast cells at sacrifice in (D) WT and 
(H) Apc
Min/+
 mice fed the RC, FF, and FF+FA diets. (* p< 0.05, ** p< 0.01, 











Figure 6.4: Circulating Levels of Myeloid Derived Suppressor Cells (MDSC) 
The circulating levels of MDSCs before initial treatment with 5-FU, after 
treatment with 5-FU, after the rest week, and at sacrifice in WT mice fed the (A) 
RC, (B) FF, and (C) FF+FA diets and in Apc
Min/+
 mice fed the (E) RC, (F) FF, and 
(G) FF+FA diets. Blue represents PBS treated mice and red represents 5-FU 
treated mice. Bar graphs represent the total percentage of mast cells at sacrifice in 
(D) WT and (H) Apc
Min/+
 mice fed the RC, FF, and FF+FA diets.  (* p< 0.05, ** 





THE ROLE OF SUCCINYL SULFATHIAZOLE
7.1 INTRODUCTION 
 In the previous sections, the FF and FF+FA diets contained 1% SST, an antibiotic 
the inhibited the production of folate by gut bacteria. The FF diet had complete 
elimination of FA by both the diet and 1% SST whereas the FF+FA diet contained FA, 
but had 1% SST. Therefore, two major questions arise:  what are the effects driven by 
folate deficiency in the diets, and what effects are driven by inhibition of folate 
production by the antibiotic, 1% SST. To delineate these effects, we performed the 
experiments using a folate deficient diet that lacks SST.   
Thus, the goal in this chapter is to examine the effect of dietary folate deficiency 
on tumor burden, hematopoietic toxicity, gut microbiome composition, SCFA 
concentrations, and the immune cell infiltration into the TME without inhibiting gut 
folate production.  
We used the same experimental designed that was previously described. 
Apc
Min/+
mice were fed the RC diet up to 10 weeks of age and then randomly assigned to 
either a basal or FF* (folate deficient diet without SST) diets. The basal and FF* diets are 
folate replete and folate defined diets respectively that do not contain SST. Similar 
analyses were completed to assess tumor burden, hematopoietic toxicity, changes in the 




7.2A: ABSENCE OF SUCCINYL SULFATHIAZOLE REVERSES TUMOR 
REGRESSION AND PROTECTION FROM HEMAOPOIETIC TOXICITY WHEN 
TREATED WITH 5-FU 
The results from these studies showed that removal of the antibiotic SST reversed 
the enhanced cytotoxicity of 5-FU therapy. The removal of SST had no significant effect 
on mouse and spleen weight (Figure 7.1A-B). Apc
Min/+
mice fed the basal and FF* diets 
had similar tumor burden (p=0.75) that remained similar when treated with 5-FU 
(p=0.69). Mice fed the basal diet that were treated with 5-FU had a 17% reduction in total 
tumor burden as compared to PBS treated controls (Basal PBS 50.79 ± 16.78 versus 
Basal 5-FU 42.31 ± 24.03; p=0.430). Mice fed the FF* diet that were treated with 5-FU 
had a 30% reduction in total tumor burden as compared to PBS treated controls (FF* PBS 
53.88 ± 20.19 versus FF* 5-FU 38.25 ± 13.16, p=0.095) (Figure 7.1 D). These results 
were also consistent for tumors that were >1mm (Figure 7.1 E). However, when Apc
Min/+
 
mice were fed the FF diet that contains 1% SST, tumor burden decreased 70% during 
treatment with 5-FU as compared to PBS treated controls. In addition, removal of SST 
caused a loss of hematopoietic protection as HCT, HGB, and RBC levels were 
significantly lower than the healthy range during treatment with 5-FU. Our data showed 
that mice fed the FF* diet were able to regain healthy measures of the hematopoietic 
parameters after three rounds of 5-FU; in contrast, mice fed the basal diet showed a 
continued decline in these parameters. These data suggest that elimination of dietary 
folate combined with inhibition of folate production by gut bacteria may protect the mice 
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from hematopoietic toxicity. Restoration of folate production by the gut microbiota was 
sufficient to increase hematopoietic toxicity of 5-FU (Figure 7.1C).  
 
7.2B: ABSENCE OF SUCCINYL SULFATHIAZOLE NORMALIZED THE GUT 
MICROBIOTA 
 The results from 16S ribosomal sequencing of genomic DNA from fecal pellets 
revealed an increase in species richness when Apc
Min/+
 mice were fed the FF* diet as 
compared to mice fed the basal diet (Figure 7.2A). In addition, there were differences in 
species diversity in mice fed the basal as compared to those on the FF diets as seen in 
weighted PCoA plot, which takes into account the relative abundance of each taxa within 
the communities (Figure 7.2B). This clear separation disappeared in the unweighted 
PCoA plot suggesting that the effects were driven by the relative abundance of specific 
taxa rather than the species present within the communities amongst the different cohorts 
(Figure 7.2C). Analysis of the gross composition shifts at the phylum level revealed that 
Bacteroidetes were the most abundant phylum present followed by the Firmicutes 
(Figure 7.2D). At the family level, the S24-7 family of the Bacteroidetes was the most 
abundant family present in the samples (Figure 7.2E). These data strongly indicate that 
inhibition of folate production by the gut microbiota rather than dietary folate deficiency 
was critical for enhancing tumor response to therapy, potentially by specifically 
eliminating the Bacteroidetes S24-7 population. Similar to previous results, the 
Firmicutes Ruminococcus and Clostridiales remained abundant suggesting that these 
microbes were not altered by the diet or SST (Figure 7.2E).  
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7.2C: BASAL AND FF* DIETS MODIFY THE SCFA CONCENTRATIONS AND 
TME COMPOSITION 
 The results from GC-FID analysis SCFAs from the cecal content indicated that 
the diets contributed to the reduction of SCFA concentrations in the cecum. Acetic, 
propionic, and butyric acids all remained low when mice were fed the basal and FF* diets 
and were similar to levels seen in the previous experiment (Figure 7.1 A-C). When mice 
were fed the basal and FF* diets, propionic acid levels increased slightly and butyric acid 
levels decreased slightly. However, none of these changes were statistically significant 
(Figure 7.3 A-C).  
 Examination of the TME revealed a significant reduction of all immune cell types 
into the TME including mast cells, macrophages, MDSCs, and t-regulatory cells. 
Cytotoxic T cells were the only cell type that were elevated when Apc
Min/+
 mice were fed 
the basal and FF diets as compared to the previous study. Perhaps the presence of the 
antibiotic SST present in the other diets promoted the infiltration of immune cells into the 
TME, such that when mice fed the FF diet with SST were treated with 5-FU, it was more 
cytotoxic to the tumors and caused their regression. It is possible that some of the 
immune cells such as MDSCs and macrophages created a TME wherein 5-FU was more 
cytotoxic to the tumor. Previous studies have shown that 5-FU is selectively cytotoxic to 
MDSCs and may recruit CD8
+
 T cells that secrete IFN-γ that aid in killing tumor cells 





7.3 SUMMARY AND DISCUSSION 
 In this chapter, we delineated the impact of the dietary folate deficiency and 
inhibition of folate production by the gut microbiota, SST, on tumor response to therapy, 
hematopoietic toxicity, metabolite concentration in the gut, and the TME composition. 
These data indicate that inhibition of FA produced by gut microbes is essential to reduce 
tumor burden in Apc
Min/+
mice in response to 5-FU. The data further suggests that folate 
from the gut microbiota can confer resistance to 5-FU by modifying the TME and 
metabolite concentrations in the gut.  
 In addition, SST also alters the gut microbiota composition by specifically 
eliminating the Bacteroidetes S24-7 population. Removing the antibiotic restored this 
population and altered tumor response to 5-FU therapy. Future studies need to examine 
the newly discovered bacterial population and the mechanisms by which it can confer 
resistance to 5-FU therapy.  
 The composition of SCFAs remains depleted in Apc
Min/+
mice fed the basal and 
FF* diets suggesting that the defined diets reduced the concentrations of SCFAs. This 
refutes our hypothesis that the changes in the gut microbiota would alter the composition 
of SCFAs. In addition, the basal and FF* diets significantly reduced the infiltration of 
mast cells, macrophages, MDSCS, and Treg cells into the TME as compared to 
Apc
Min/+
mice fed the RC diet. In addition, the recruitment of mast cells and Treg cells 
into the TME were significantly reduced in mice fed the basal or FF* diets that were 
treated with PBS or 5-FU as compared to mice fed the FF+FA or FF diets containing 1% 
SST that were treated with PBS or 5-FU (data not shown). The recruitment of 
macrophages and MDSCs into the TME were also significantly reduced in mice fed the 
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basal or FF* diets as compared to the mice fed the FF+FA and FF diets, with the 
exception of mice fed the FF* and FF diets that were treated with PBS (Macrophages 
P=.14; MDSCs P=.14). These results showed that the folate deficiency reduced the 
infiltration of macrophages and MDSCs, regardless of the presence of SST. Finally, there 
was no significant difference in the infiltration of CD8
+
 T cells between mice fed the 
basal and FF* diets that were treated with PBS or 5-FU as compared to mice fed the 
FF+FA and FF diets, with the exception of mice fed the FF* and FF diets that were 
treated with 5-FU (p=0.034). Overall, the infiltration of these immune cells increased 
when Apc
Min/+
mice were fed the FF and FF+FA diets that contain SST suggesting that the 
antibiotic is responsible for the enhanced infiltration of immune cells into the TME. Yet, 
the infiltration of these immune cells into the TME remains significantly reduced in mice 
fed the basal. FF*, FF, and FF+FA diets compared to mice fed the RC diet. It is possible 
that the absence or presence of these immune cells is functioning to create an anti-
tumorigenic TME to promote tumor regression and rejection. Future studies will 
























Figure 7.1: Loss of Succinyl Sulfathiazole on Mouse and Spleen Weight, 
Hematopoietic Parameters, and Tumor Burden.  Changes in (A) mouse 
weight and (B) spleen weight in Apc
Min/+
 mice fed the RC, basal, and FF diets 
and treated with PBS (blue) or 5-FU (red). C. The hematopoietic parameters of 
Apc
Min/+
mice fed the basal and FF diets. Solid lines represent mice fed the 
basal diet and dashed lines represent mice fed the FF diet. The yellow bar is 
indicative of the healthy range for each hematopoietic parameter.  D. Total 
tumor burden and tumors >1mm in Apc
Min/+
 mice fed the basal and FF diets 
and treated with PBS or 5-FU. E. Total tumor burden of Apc
Min/+
 mice fed the 
RC and basal diets and treated with PBS (blue) or 5-FU (red). (* p< 0.05, ** 























Figure 7.2: Loss of Succinyl Sulfathiazole on the Gut Microbiota. Alpha 
diversity by rarefaction plot of ApcMin/+ mice fed the basal and FF diets. Beta 
diversity (B) weighted and (C) unweighted principal component plots of Apc
Min/+
 
mice fed the basal and FF diets. (D) Phylum and (E) family gross compositional 
shifts amongst Apc
Min/+































Figure 7.3: SCFA levels and Immune Cells in the TME in Mice fed the Basal 
and FF* Diets. Changes in the abundance of (A) acetic acid, (B) propionic acid, 
and (C) butyric acid in Apc
Min/+
 mice fed the basal and FF diets and treated with  
PBS (blue) or 5-FU (red). Changes in the abundance of (D) mast cells, (E) 
macrophages, (F) granulocytes, (G) t-regulatory cells, and (H) cytotoxic T cells 
in APC
Min/+
 mice fed the basal and FF diets and treated with PBS (blue) or 5-FU 






PROPOSED MECHANISM OF A FOLATE DEFICIENCY AND CHEMOTHERAPY 
ON TUMOR RESPONSE
8.1 INTRODUCTION 
 The results from these studies provide the mechanism for which a FF diet 
contributes to enhanced cytotoxicity of 5-FU. Apc
Min/+
mice fed the FF diet had a 
significant reduction in spleen weight as compared to Apc
Min/+
 mice fed the RC and 
FF+FA diets that remained low during treatment with 5-FU. The body weight increased 
significantly as well when Apc
Min/+
 mice fed the FF diet were treated with 5-FU therapy. 
These mice had the highest body weight at the time of sacrifice as compared to Apc
Min/+
 
mice fed the RC and FF+FA diets. In addition, Apc
Min/+
 mice fed the FF diet recovered 
healthy levels of HCT, HGB, and RBCs after one round of 5-FU therapy. The presence of 
FA in the FF+FA diet reversed these beneficial effects. Apc
Min/+
mice fed the FF+FA diet 
had a reduced spleen weight that significantly increased upon treatment with 5-FU to 
levels observed in Apc
Min/+
 mice fed the RC diet. These mice also required three rounds 
to 5-FU therapy to recover healthy levels of HCT, HGB, and RBCs.  
 Apc
Min/+
mice fed either the RC, FF, or FF+FA diets had no significant difference 
in tumor burden suggesting that dietary manipulation alone was not sufficient to reduce 
tumor development. However, upon systemic treatment with 5-FU, Apc
Min/+
mice fed the 
FF diet had at significant 70% reduction in tumor burden surpassing Apc
Min/+
 mice fed the 
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RC and FF+FA diets. It is evident that removal of dietary folate and folate production by 
gut microbes enhances the cytotoxic effects of 5-FU. 
Analysis from 16S ribosomal sequencing of fecal pellets showed that 
Apc
Min/+
mice on the FF and FF+FA diets had a significant reduction in the Bacteroidetes 
S24-7 family and an expansion of the Firmicutes Ruminococcus and Clostridiales 
families as compared to mice fed the RC diet. These gross compositional changes are a 
direct result of the presence of SST in the diet, as removal of SST in the basal and FF* 
diets reversed these effects.  In addition, mice fed the FF and FF+FA diets had a 
significant reduction in acetic, propionic, and butyric acids as compared to mice fed the 
RC diet. The Bacteroidetes phylum is major producers of propionic and acetic acids 
whereas the Firmicutes phylum is major producers of butyric acid respectively. Despite 
the fact that the levels of butyric acid decreased, the Firmicutes phylum expanded. 
However, acetic acid is used as a CoA-transferase for the conversion of butyryl-CoA to 
butyrate (Louis and Flint). It is likely that the reduction in acetic acid is removing the co-
factor required to form butyrate and decreasing the concentration of butyrate in the 
cecum.  
 These changes in the gut microbiota and SCFA composition reduced the 
recruitment of immune cells into the TME. Mice fed the FF and FF+FA diets had a 
significant reduction in mast cells, macrophages, granulocytes, Treg cells, and cytotoxic 
T cells as compared to mice fed the RC diet. These data also correlated with the reduction 
of circulating MDSCs and macrophages suggesting that a FF diet enhances anti-tumor 
immunity.  
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 Upon removing SST using the basal and FF* diets, it is evidence that altering the 
gut microbiota is essential to enhance the cytotoxic effects of 5-FU. The gut microbiota 
composition of mice fed the basal and FF* diets was normalized, such that the 
Bacteroidetes S24-7 was abundant. The distribution of Bacteroidetes S24-7 and the 
Firmicutes Ruminococcus and Costridiales shared similar abundance to WT and Apc
Min/+
 
mice fed the RC diet. However, the SCFA concentrations remained consistent to levels 
present in mice fed the FF and FF+FA diets suggesting that the changes in the gut 
microbiota by SST are not altering the composition of SCFAs. In mice fed the basal and 
FF* diets, the recruitment of immune cells into the TME was reduced as compared to 
mice fed the FF+FA and FF diets that contain 1% SST. Understanding how the specific 
abundance of these immune cells in the TME enhances the cytotoxicity of 5-FU still 
needs to be established.  
These results suggest that the defined diets are responsible for reducing the 
composition of SCFAs and the recruitment of immune cells into the TME, whereas the 
antibiotic is responsible for targeting and manipulating the gut microbiota. If we do not 
alter the gut microbiota, 5-FU is unable to effectively kill the tumors. In conclusion, 
administering a folate deficient diet that contains SST to inhibit the production of folate 
by gut microbes is essential to alter the gut microbiota to maximize the cytotoxicity of 5-
FU therapy. Our results confirm that it is essential block dietary folate and folate 
produced by the gut microbiota to enhance the cytotoxic effects of 5-FU therapy. The 
schematic diagram provides our proposed mechanism (Figure 8.1).  
 Future studies will determine the impact of SST in mice fed a RC diet. Using the 
same experimental design, mice will receive either RC or RC + 1% SST diets to 
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determine if altering the gut microbiota is sufficient to enhance the cytotoxic effects of 5-
FU. If mice can be administered a regular chow diet that contains an antibiotic to alter the 
gut microbiota, then perhaps altering the gut microbiota of patients in the clinical setting 
would enhance the cytotoxic effects of 5-FU, without requiring drastic changes to their 
diet. Nonetheless, it is essential to determine whether folate needs to be eliminated from 
the diet, the gut microbiome, or both.  In addition, future studies will examine the activity 
of immune cells in the TME. Using the same experimental design, mice will be 
euthanized after one and three rounds of 5-FU therapy to determine how 5-FU influences 
the activation and infiltration of immune cell populations and how this contributes to 
enhanced cytotoxicity of 5-FU. In addition, characterizing the immune cell populations, 
to delineate pro-inflammatory M1 or anti-inflammatory M2 macrophages among others, 





Figure 8.1: Schematic Diagram. This study showed that Apc
Min/+
 mice fed a 
folate deficient diet with 1% SST had a significant reduction of the Bacteroidetes 
S24-7 and an expansion of the Firmicutes Ruminococcus and Clostridiales. 
Subsequently, the composition of SCFAs, specifically propionic, acetic, and 
butyric acid were significantly reduced. Our data suggests that altering the gut 
microbiota through a folate deficient diet significantly reduced the recruitment of 
mast cells, macrophages, MDSCs, Treg cells, and cytotoxic T cells. This altered 
gut microbiota and TME creates an anti-tumorigenic microenvironment to 
enhance the cytotoxicity of 5-FU therapy to promote tumor regression and 









mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Animal procedures were performed according to the guidelines and 




Rodent chow 5001 (RC) (LabDiet, St. Louis MO) was used as our regular diet 
control. Folate free 58C3 (FF) and folate free + 6ppm (parts per million) folic acid 57KH 
(FF+FA) diets were synthesized (TestDiet, St. Louis, MO). Both diets are identical with 
the exception that the FF+FA diet contains 6ppm of folic acid. Both diets contain 1% 
succinylsulfathiazole, an antibiotic that reduces folate production and interferes with 
folate absorption and metabolism. This experimental design allows us to distinguish the 
impact of folate consumed in the diet and the impact of folate producing bacteria. Basal 
and FF diets were synthesized (TestDiet, St. Louis, MO). These diets are identical except 
the basal contains 6ppm folic acid and the FF contains no folic acid. Neither of these 





Blood was collected in Heparin-coated capillary tubes and stored in EDTA coated 
vials (Thermofisher, Pittsburg, PA; Becton Dickinson, Franklin Lakes, NJ) through the 
retro-orbital vein. Blood samples were analyzed using the VetScan HM5 Hematology 
Analyzer (Abaxis, Union City, CA). Samples were centrifuged at 10,000 g for five 
minutes to pellet the RBCs. The supernatant containing serum was stored in 
microcentrifuge tubes at -80°C until further analysis.   
 
Pellet Collection 
Animals were placed in individually clean cages without bedding. Pellets were 
collected from the bottom of the cage using sterilized tweezers and placed into clean 




 5-FU was prepared at 4mg/mL in 1x PBS and filter sterilized using a .2µm filter. 
Mice were weighed prior to each dosing and administered 40mg/kg of 5-FU. Mice 
received an intraperitoneal injection if 5-FU using a 21G syringe.  
 
Sacrifice  
 Mice were euthanized by cervical dislocation and tissues were immediately 
harvested. The spleen and liver were excised, weighed, and cut into two fragments. One 
fragment was flash frozen in dry ice and ethanol and the other fragment was placed in 4% 
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paraformaldehyde (PFA). The cecum was excised and flash frozen in dry ice and ethanol. 
The small intestines of Apc
Min/+
mice were cut into four equal parts. The small intestines 
and colon were flushed with PBS and cut down the middle to lay the intestines flat on 
whatman filter paper. Four intestine segments and one colon segment were stored in 4% 
PFA overnight and moved to 1% PFA the next day.  
 
Tumor Counting 
Intestines were harvested from the animals, cut open and positioned flat on filter 
paper. Intestines were cut into four segments for the small intestine plus one segment for 
the colon. Tumors were counted using .1% methylene blue stain. Tumors were counted 
from each segment of the intestines for total tumor count and tumors >1mm.   
 
Stool Isolation 
DNA was isolated from pellets using the QIAamp DNA Stool Mini Kit (Qiagen). 
Pellets were isolated following their procedure provided on their website. Pellets were 
homogenized in ASL buffer. The supernatant was collected and resuspended with an 
InhibitEX Tablet. The solution was centrifuged and the supernatant was collected, and 
mixed with AL buffer and proteinase K. The solution was incubated at 70⁰ C for 10 
minutes. Ethanol was added to the mixture and centrifuged through the QIAamp spin 
column. Spin column was washed once with AW1 buffer and twice with AW2 buffer. 
DNA was eluted in AE buffer and stored at -20⁰ C until further dilution for 16S 
ribosomal sequencing.  
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16S Ribosomal Sequencing 
DNA isolated from pellets underwent 16S ribosomal metagenomics sequencing 
using the NextSeq500 Next Generation Sequencing instrument (Illumina, San Diego, 
CA). V3 and V4 regions were PCR amplified using gene-specific primers. Amplified 
regions were purified using beads to remove the primers from the amplicon. This PCR 
clean up step occurs twice. Libraries were quantified using dsDNA fluorometric 
quantification binding dyes. Libraries were denatured for cluster generation and 
sequencing. Control and amplicon libraries were loaded into MidSeq to classify the reads 
at each taxonomic level. R1 and R2 FASTQ files were generated and analyzed using 
QIIME data software.  
 
Gas Chromatography – Flame Ionization Detector 
 The gas chromatography – flame ionization detector (GC-FID) technique was 
used on mouse cecal content to study short chain fatty acids (SCFAs). The SCFAs of 
interest are acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, and 
valeric acid (Sigma, St. Louis, MO). 2-ethyl butyric acid (Sigma, St. Louis, MO) was 
used as an internal control. Approximately 50 mg of cecal content was weighed, 
recorded, and placed into a microcentrifuge tube. One milliliter of 0.5% phosphoric acid 
solution diluted in water was added to the cecal content. In addition, five microliters of 
10mM 2-ethyl butyric acid solution diluted in water was added. One mm zirconium oxide 
beads (NextAdvance, Troy, NY) were added to the microcentrifuge tube to homogenize 
the cecal content. Samples were centrifuged at 13,000 RPM for 10 minutes and the 
supernatant was removed and placed into a fresh microcentrifuge tube. 400uL of methyl 
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tert-butyl ether (MTBE) was added to the tube and the sample was vortexed for 30 
seconds. Samples were centrifuged again at 13,000 RPM for 10 minutes. The supernatant 
was removed and placed in a polytetrafluoroethylene (PTFE) cap-sealed two milliliter 
glass vial (VWR, West Chester, PA) to be processed.    
 Standard curve was generated by determining the amount of each SCFA present 
in 50 mg of cecal content. For each SCFA, seven standards were made to cover the 
micromolar (µM) range of SCFA abundance: acetic acid (150-12,000 µM), propionic 
acid (25-2,000 µM), isobutyric acid (5-1,000 µM), butyric acid (5-1,000 µM), isovaleric 
acid (5-1,000 µM), and valeric acid (1-1,000 µM). Standard curve was used to determine 






mice were selected for tissue processing from the following six 
treatment groups: RC+ PBS, RC + 5-FU, FF + PBS, FF + 5-FU, FF+FA + PBS, FF+FA 
+ 5-FU. Mouse tissues that were selected had a tumor burden nearest the mean tumor 
burden within the treatment group. From each intestine, a total of three tumors were 
processed and imaged yielding a total of nine tumors per treatment group.  
Intestines were fixed in 4% PFA in PBS at pH 7.2. One tumor and surrounding 
healthy intestines was excised and embedded in 13% acrylamide + ammonium persulfate. 
Embedded tissues were stored at 4⁰ C for 45 minutes. Tissues were then cut at 200µm 
thickness using the vibratome tissue slicer. Cut tissues were placed in 1% PFA in 




Tissues were stained for the presence of t-regulatory (treg) cells (CD4 and 
FoxP3), mast cells (CD117 and FcεR1α
+
), cytotoxic T cells (CD8), macrophages (F4/80), 
and granulocytes (Gr1).  Samples were stained with primary antibodies: CD4 (goat pAb 
sc-1140, Santa Cruz Biotechnology, Dallas, Texas), Foxp3 (rabbit pAb ab54501, Abcam, 
Cambridge, United Kingdom), CD117 (rabbit pAb LS-191740, LifeSpan BioSciences, 
Seattle, Washington), FcεR1α (goat pAb sc-33484, Santa Cruz Biotechnology, Dallas, 
Texas), CD8 (rat mAb ab22378, Abcam, Cambridge, United Kingdom), F4/80 (rat mAb 
ab16911, Abcam, Cambridge, United Kingdom), Gr1 (rat mAb 108401, Biolegend, San 
Diego, California). Samples were stained with secondary antibodies: Cy-2 anti-goat 705-
225-147, Cy-3 anti-rabbit 711-165-152, and Cy-3 anti-rat 712-165-153 (Jackson 
ImmunoResearch, West Grove, PA). Nuclei were stained with 4’, 6-diamidino-2-
phenylindole (DAPI) (Life Technologies, Eugene, OR) at a 1:5,000 dilution. Filamentous 
actin (F-actin) was stained with phalloidin AF488 A12379 and AF633 A22284 (Life 
Technologies, Eugene, OR). 
Tissues were washed with PBS, 0.01 Glycine, 0.1% Triton-X three times for 30 
minutes and blocked with 5% bovine serum albumin (BSA) in PBS and 5% Normal 
Donkey Serum (NDS) (Jackson ImmunoResearch, West Grove, PA) in 1% BSA in PBS 
for one hour. Primary antibody was applied at a 1:100 dilution and incubated at 37°C for 
one hour. Tissues were washed in 1% BSA two times for 15 minutes and blocked in 5% 
NDS in 1% BSA in PBS for one hour. Secondary antibody was applied at a 1:100 
dilution and incubated at 37°C for one hour. Tissues were washed in 1% BSA two times 
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for 15 minutes and once in PBS for 15 minutes. Phalloidin in PBS was applied at a 1:50 
dilution and incubated at room temperature for two hours. Tissues were rinsed in PBS 
three times for 15 minutes. DAPI was applied at a 1:5,000 dilution for 15 minutes. 
Finally, tissues were rinsed in PBS for 15 minutes followed by mounting tissue sections 
to slides.  
Tissues were mounted onto microscope slides using 80µL of 1, 4-Diazabicyclo 
(2.2.2) octane (DABCO). Fragments of cover glass were on the sides of the tissues 
section to elevate the coverslip and prevent distorting the tissue. Edges of the coverslip 
were sealed with a thin layer of clear nail polish. Slides were stored at 4°C.  
 
Confocal Microscopy 
 Mounted tissue slides were imaged using the Zeiss LSM 510 META Confocal 
Scanning Laser Microscope at 20x magnification. The entire region of the tumor was 
imaged to detect the total number of an immune cell population in the tumor region.  
 
Tumor Size Measures 
 Tumor sections were imaged at 4x magnification on the EVOS FL Auto cell 
Imaging System (Invitrogen, Frederick, MD). Tiff files were uploaded to ImageJ 
software (NIH, Bethesda, MA), and the region of interest function was utilized to 
measure the size of the tumor region in pixels. Immune cell counts per tumor were 





 Flow Cytometry 
 70µL of blood was collected from mice and lysed in 1x RBC lysis buffer at room 
temperature for 15 minutes. Samples were centrifuged at 2,500 rotations per minute 
(RPM) for five minutes. Supernatant was removed and the pellet was resuspended in 
1mL 1% BSA in PBS containing CD16/32 Fc blocker (101302, Biolegend, San Diego, 
CA). Samples incubated with Fc blocker for 10 minutes to prevent false positive results 
from antibodies binding to the Fc region of immune cells rather than the FaB region. 
Samples were again centrifuged and resuspended in respective antibody cocktails. The 
following conjugated monoclonal antibodies were used: CD117 (PE 105808), FcEr1a 
(PE Cy-7 134318), CD11B (PE 101208), F4/80 (AF647 123122), Gr1 (eFluor450 
108430) (Biolegend, San Diego, CA). Antibody cocktails were incubated with sample at 
room temperature for 45 minutes. Solution was centrifuged and resuspended in 500uL of 
1% BSA in PBS and immediately analyzed using the BD FACS ARIA cell sorter.   
 
Statistical Analysis 
Data was expressed as the mean +_ standard deviation (SD). Statistical analysis of 
two value sets was compared using a two-tailed t-test with Welch’s correction using 
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